HOME
login
history
all enzymes
BRENDA home
History
Enzyme Nomenclature
Information on EC 2.5.1.58 - protein farnesyltransferase
for references in articles please use BRENDA:EC2.5.1.58
Word Map on EC 2.5.1.58
- 2.5.1.58
-
farnesylation
-
prenylation
-
geranylgeranylation
-
isoprenoids
-
peptidomimetic
-
geranylgeranyltransferase-i
- ggtase-i
-
beta-subunits
-
lamins
- manumycin
-
prelamin
-
15-carbon
- tetrapeptide
-
p21ras
-
farnesyl-protein
-
oncoproteins
- medicine
-
isoprenylation
- lonafarnib
-
ras-induced
-
geranyl
-
anti-ras
-
ras-transformed
-
ggtis
- farnesol
-
dimethylallyl
-
ras-mediated
-
3hmevalonate
- drug development
-
progerin
-
ras-dependent
- tetrahydroquinoline
-
hutchinson-gilford
- pharmacology
-
ki-ras
-
isopentenyl
- geranylgeraniol
-
imidazole-containing
- isoprene
- lovastatin
- tipifarnib
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
EC NUMBER 
COMMENTARY 
2.5.1.58
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
RECOMMENDED NAME
GeneOntology No.
protein farnesyltransferase
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
farnesyl diphosphate + protein-cysteine = S-farnesyl protein + diphosphate
leucine makes the protein a substrate for EC 2.5.1.59. The enzymes are relaxed in specificity for A1, but cannot act if A2 is aromatic. Substrates of prenyltransferases include Ras, Rho, Rab, other Ras-related small GTP-binding proteins, gamma-subunits of heteotrimeric G-proteins, nuclear lamins, centromeric proteins and many proteins involved in visual signal transduction. A zinc metalloenzyme that requires Mg2+ for activity; This enzyme, along with geranylgeranyltransferase types I, EC 2.5.1.59 and II, EC 2.5.1.60, constitutes the protein prenyltransferase family of enzymes. Catalyses the formation of a thioether linkage between the C-1 of an isoprenyl group and a cysteine residue fourth from the C-terminus of the protein. These protein acceptors have the C-terminal sequence CA1A2X, where the terminal residue, X, is preferably serine, methionine, alanine or glutamine
-
-
-
farnesyl diphosphate + protein-cysteine = S-farnesyl protein + diphosphate
enzyme constitutes the protein prenyltransferase family of enzymes; farnesyl diphosphate binds the enzyme in a two step process that may involve an enzyme conformational change, the enzyme-substrate complex then rapidly reacts with the peptide substrate to form a product, and product release is the rate-limiting step in catalysis; kinetic mechanism
-
farnesyl diphosphate + protein-cysteine = S-farnesyl protein + diphosphate
farnesyl diphosphate binds the enzyme in a two step process that may involve an enzyme conformational change, the enzyme-substrate complex then rapidly reacts with the peptide substrate to form a product, and product release is the rate-limiting step in catalysis; kinetic mechanism
-
farnesyl diphosphate + protein-cysteine = S-farnesyl protein + diphosphate
farnesyl diphosphate binds exclusively to the beta subunit
-
farnesyl diphosphate + protein-cysteine = S-farnesyl protein + diphosphate
enzyme constitutes the protein prenyltransferase family of enzymes; The enzyme preferentially farnesylates CaaX sequences ending in methionine, cysteine or serine. Enzyme also attaches geranylgeraniol to some CaaX sequences ending in methionine, leucine and cysteine. Substrate overlap may occur between the Saccharomyces cerevisae farnesyl transferase and geranylgeranyltransferase types I in vivo
-
farnesyl diphosphate + protein-cysteine = S-farnesyl protein + diphosphate
kinetic mechanism
-
farnesyl diphosphate + protein-cysteine = S-farnesyl protein + diphosphate
both subunits would appear to have a role in binding and orienting the leaving group of farnesyl diphosphate approximately for catalysis
-
farnesyl diphosphate + protein-cysteine = S-farnesyl protein + diphosphate
enzyme constitutes the protein prenyltransferase family of enzymes; kinetic mechanism
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
farnesyl-diphosphate:protein-cysteine farnesyltransferase
This enzyme, along with protein geranylgeranyltransferase types I (EC 2.5.1.59) and II (EC 2.5.1.60), constitutes the protein prenyltransferase family of enzymes. Catalyses the formation of a thioether linkage between the C-1 of an isoprenyl group and a cysteine residue fourth from the C-terminus of the protein. These protein acceptors have the C-terminal sequence CA1A2X, where the terminal residue, X, is preferably serine, methionine, alanine or glutamine; leucine makes the protein a substrate for EC 2.5.1.59. The enzymes are relaxed in specificity for A1, but cannot act if A2 is aromatic. Substrates of the prenyltransferases include Ras, Rho, Rab, other Ras-related small GTP-binding proteins, gamma-subunits of heterotrimeric G-proteins, nuclear lamins, centromeric proteins and many proteins involved in visual signal transduction. A zinc metalloenzyme that requires Mg2+ for activity.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
131384-38-8
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
tachyzoites of the RH strain were grown and maintained in Cercopithecus aethiops kidney cells
-
-
alpha-subunit Crfta/ggt_Ia, common subunit of EC 2.5.1.58 and EC 2.5.1.59
Q6EZ49
SwissProt
-
637505, 637506, 637523, 658092, 658829, 659721, 675037, 675272, 675320, 685102, 685588, 685591, 685858, 686084, 686526, 687326, 688024, 689134, 702691, 703175, 704851, 721819, 722790, 722871, 737819, 738158, 738969
-
-
-
637499, 637501, 637502, 637503, 637504, 637505, 637509, 637512, 637513, 637514, 637515, 637517, 637521, 637522, 637523, 637525, 658096, 658276, 659292, 671996, 673051, 675079, 677189, 685608, 688254, 689134, 702274, 702644, 703175, 703207, 705065, 705172, 705242, 721674, 722188
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
physiological function
additional information
malfunction
combined FTase/GGTase-I deficiency significantly reduces K-Ras-induced lung tumors and improves survival without obvious pulmonary toxicity. Enzyme deficiency is involved in progeria, also known as Hutchinson-Gilford progeria syndrome, a fatal and rare genetic disease caused by the mutation of the LMNA gene
malfunction
combined FTase/GGTase-I deficiency significantly reduces K-Ras-induced lung tumors and improves survival without obvious pulmonary toxicity; combined FTase/GGTase-I deficiency significantly reduces K-Ras-induced lung tumors and improves survival without obvious pulmonary toxicity
physiological function
-
posttranslational modification of proteins involved in intracellular signal transduction network
physiological function
-
posttranslational modification of proteins involved in intracellular signal transduction network
physiological function
-
posttranslational modification of proteins involved in intracellular signal transduction network
physiological function
-
key negative regulator controlling abscisic acid sensitivity
physiological function
-
ras1 deletion phenotype can be mimicked chemically by inhibition of farnesyl transferase in the wild-type strain
physiological function
farnesyltransferase alpha subunit regulates vacuolar protein sorting-associated protein 4A (Vps4A)-dependent intracellular trafficking through recycling endosomes. The enzyme FTase alpha controls trafficking of transferrin receptor upstream of thie Vps4A protein
physiological function
farnesyltransferase alpha subunit regulates vacuolar protein sorting-associated protein 4A (Vps4A)-dependent intracellular trafficking through recycling endosomes. The enzyme FTase alpha controls trafficking of transferrin receptor upstream of thie Vps4A protein
physiological function
FTase catalyzes farnesyl isoprenoid linked to the cysteine residue of the CAAX protein through a thioether linkage, which will enhance the hydrophobicity of the CAAX protein. Meanwhile, the formed CAAX-protein-isoprenoid complex is attached to the endoplasmic reticulum surface. FTase is involvedin hematologic malignancies due via prenylation of Ras. The enzyme is also important in the pathological process of neurological diseases, such as neuroinflammatory disease and Parkinson's disease
physiological function
FTase catalyzes farnesyl isoprenoid linked to the cysteine residue of the CAAX protein through a thioether linkage, which will enhance the hydrophobicity of the CAAX protein. Meanwhile, the formed CAAX-protein-isoprenoid complex is attached to the endoplasmic reticulum surface; FTase catalyzes farnesyl isoprenoid linked to the cysteine residue of the CAAX protein through a thioether linkage, which will enhance the hydrophobicity of the CAAX protein. Meanwhile, the formed CAAX-protein-isoprenoid complex is attached to the endoplasmic reticulum surface
physiological function
-
protein prenylation is a posttranslational modification critical for many cellular processes such as DNA replication, signaling, and trafficking. Protein farnesyltransferase recognizes the CAAX motif on the protein substrate
physiological function
-
ras1 deletion phenotype can be mimicked chemically by inhibition of farnesyl transferase in the wild-type strain
-
additional information
Q9Y765 AND A0A0A6KLS8
comparison of the substrate specificities of PFTases from three organisms, Rattus norvegicus, Saccharomyces cerevisiae, and Candida albicans, using CVa2X libraries, overview. Rattus norvegicus PFTase shares more peptide substrates with Saccharomyces cerevisiae PFTase than with Candida albicans PFTase
additional information
-
comparison of the substrate specificities of PFTases from three organisms, Rattus norvegicus, Saccharomyces cerevisiae, and Candida albicans, using CVa2X libraries, overview. Rattus norvegicus PFTase shares more peptide substrates with Saccharomyces cerevisiae PFTase than with Candida albicans PFTase
additional information
P29703 AND P22007
comparison of the substrate specificities of PFTases from three organisms, Rattus norvegicus, Saccharomyces cerevisiae, and Candida albicans, using CVa2X libraries, overview. Rattus norvegicus PFTase shares more peptide substrates with Saccharomyces cerevisiae PFTase than with Candida albicans PFTase
additional information
ligand interaction analysis with FTase alpha subunit, mass spectrometry, overview. Modelling of dimeric FTase alpha subunits
additional information
ligand interaction analysis with FTase alpha subunit, mass spectrometry, overview. Modelling of dimeric FTase alpha subunits
additional information
FTase and GGTase-I recognize the same CAAX sequence motif in a protein substrate and catalyze the attachment of farnesyl and geranygeranyl groups to the protein, respectively. The X is the key residue that determines the farnesylation or geranylgeranylation of the CAAX-containing protein. When X is serine, methionine or glutamine the protein substrate is preferentially activated by FTase, but when X is leucine or phenylalanine the protein substrate is preferentially activated by GGTase-I
additional information
FTase and GGTase-I recognize the same CAAX sequence motif in a protein substrate and catalyze the attachment of farnesyl and geranygeranyl groups to the protein, respectively. The X is the key residue that determines the farnesylation or geranylgeranylation of the CAAX-containing protein. When X is serine, methionine or glutamine the protein substrate is preferentially activated by FTase, but when X is leucine or phenylalanine the protein substrate is preferentially activated by GGTase-I
additional information
FTase and GGTase-I recognize the same CAAX sequence motif in a protein substrate and catalyze the attachment of farnesyl and geranygeranyl groups to the protein, respectively. The X is the key residue that determines the farnesylation or geranylgeranylation of the CAAX-containing protein. When X is serine, methionine or glutamine the protein substrate is preferentially activated by FTase, but when X is leucine or phenylalanine the protein substrate is preferentially activated by GGTase-I; FTase and GGTase-I recognize the same CAAX sequence motif in a protein substrate and catalyze the attachment of farnesyl and geranygeranyl groups to the protein, respectively. The X is the key residue that determines the farnesylation or geranylgeranylation of the CAAX-containing protein. When X is serine, methionine or glutamine the protein substrate is preferentially activated by FTase, but when X is leucine or phenylalanine the protein substrate is preferentially activated by GGTase-I
additional information
FTase and GGTase-I recognize the same CAAX sequence motif in a protein substrate and catalyze the attachment of farnesyl and geranygeranyl groups to the protein, respectively. The X is the key residue that determines the farnesylation or geranylgeranylation of the CAAX-containing protein. When X is serine, methionine or glutamine the protein substrate is preferentially activated by FTase, but when X is leucine or phenylalanine the protein substrate is preferentially activated by GGTase-I; FTase and GGTase-I recognize the same CAAX sequence motif in a protein substrate and catalyze the attachment of farnesyl and geranygeranyl groups to the protein, respectively. The X is the key residue that determines the farnesylation or geranylgeranylation of the CAAX-containing protein. When X is serine, methionine or glutamine the protein substrate is preferentially activated by FTase, but when X is leucine or phenylalanine the protein substrate is preferentially activated by GGTase-I
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(1E)-1-[(2E,6E,10E)-12-azido-3,7,11-trimethyldodeca-2,6,10-trien-1-ylidene]-2-oxodiphosphane + protein-cysteine
?
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-(2,3,5,6-tetrafluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(2,3,5,6-tetrafluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-(phenylamino)octa-2,6-dien-1-yl diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-(phenylamino)octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-(phenylsulfanyl)octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-(phenylsulfanyl)octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-(prop-2-yn-1-yloxy)octa-2,6-dien-1-yl diphosphate + CCIQ
?
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-(prop-2-yn-1-yloxy)octa-2,6-dien-1-yl diphosphate + CGGDD
?
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-(prop-2-yn-1-yloxy)octa-2,6-dien-1-yl diphosphate + CSVL
?
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-(prop-2-yn-1-yloxy)octa-2,6-dien-1-yl diphosphate + CTIQ
?
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-(prop-2-yn-1-yloxy)octa-2,6-dien-1-yl diphosphate + CVIS
?
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-(prop-2-yn-1-yloxy)octa-2,6-dien-1-yl diphosphate + CVLL
?
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-(prop-2-yn-1-yloxy)octa-2,6-dien-1-yl diphosphate + CVLS
?
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-phenoxyocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-phenoxyocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[(2-methylphenyl)amino]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[(2-methylphenyl)amino]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[(3,4,5-trimethoxybenzyl)oxy]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[(3,4,5-trimethoxybenzyl)oxy]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[(3-methylphenyl)amino]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[(3-methylphenyl)amino]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[(4-methylphenyl)amino]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[(4-methylphenyl)amino]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[(4-nitrophenyl)amino]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[(4-nitrophenyl)amino]octa-2,6-dien-1-y)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[3-(1-methylethyl)phenoxy]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[3-(1-methylethyl)phenoxy]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[3-(trifluoromethoxy)phenoxy]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[3-(trifluoromethoxy)phenoxy]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[3-(trifluoromethyl)phenoxy]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[3-(trifluoromethyl)phenoxy]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[4-(1-methylethyl)phenoxy]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[4-(1-methylethyl)phenoxy]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[4-(trifluoromethoxy)phenoxy]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[4-(trifluoromethoxy)phenoxy]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[[2-(trifluoromethyl)phenyl]amino]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[[2-(trifluoromethyl)phenyl]amino]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[[3-(trifluoromethoxy)phenyl]amino]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[[3-(trifluoromethoxy)phenyl]amino]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-8-[[4-(trifluoromethoxy)phenyl]amino]octa-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-8-[[4-(trifluoromethoxy)phenyl]amino]octa-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-3,7-dimethyl-9-phenylnona-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-3,7-dimethyl-9-phenylnona-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(2,3-difluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(2,3-difluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(2,6-difluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(2,6-difluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(2-bromophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(2-bromophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(2-ethylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(2-ethylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(2-fluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(2-fluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yll)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(2-iodophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(2-iodophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(3,4-dichlorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(3,4-dichlorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(3,4-difluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(3,4-difluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(3,5-dichlorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(3,5-dichlorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(3,5-difluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(3,5-difluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(3-bromophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(3-bromophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(3-cyanophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(3-cyanophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(3-ethylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(3-ethylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(3-fluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(3-fluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yll)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(3-iodophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(3-iodophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(4-benzylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(4-benzylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(4-bromophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(4-bromophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(4-cyanophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(4-cyanophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(4-ethylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(4-ethylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(4-fluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(4-fluorophenoxy)-3,7-dimethylocta-2,6-dien-1-yll)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(4-iodophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(4-iodophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(4-nitrophenoxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(4-nitrophenoxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(benzyloxy)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(benzyloxy)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-(isoxazol-3-ylamino)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-(isoxazol-3-ylamino)-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(2-ethylphenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(2-ethylphenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(2-fluorophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(2-fluorophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(2-methoxyphenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(2-methoxyphenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(3-bromophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(3-bromophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(3-cyanophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(3-cyanophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(3-ethylphenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(3-ethylphenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(3-fluorophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(3-fluorophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(3-iodophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(3-iodophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(3-methoxyphenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(3-methoxyphenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(4-bromophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(4-bromophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(4-cyanophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(4-cyanophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(4-fluorophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(4-fluorophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(4-iodophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(4-iodophenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[(4-methoxyphenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[(4-methoxyphenyl)amino]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[3-(hydroxymethyl)phenoxy]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[3-(hydroxymethyl)phenoxy]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-8-[4-(hydroxymethyl)phenoxy]-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-8-[4-(hydroxymethyl)phenoxy]-3,7-dimethylocta-2,6-dien-1-yl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + (protein)-L-cysteine
S-(2E,6E)-farnesyl protein + diphosphate
(2E,6E)-farnesyl diphosphate + CCIQ
S-(2E,6E)-farnesyl-CCIQ + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + CGGDD
S-(2E,6E)-farnesyl-CGGDD + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + CSVL
S-(2E,6E)-farnesyl-CSVL + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + CTIQ
S-(2E,6E)-farnesyl-CTIQ + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + CVIS
S-(2E,6E)-farnesyl-CVIS + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + CVLL
S-(2E,6E)-farnesyl-CVLL + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + CVLS
S-(2E,6E)-farnesyl-CVLS + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + dansyl-CGVLS
dansyl-G-(S-(2E,6E)-farnesyl)CVLS
-
assay at pH 7.5, 37°C
-
-
?
(2E,6E)-farnesyl diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-farnesyl)CVLS
-
assay at pH 7.5, 30°C
-
-
?
(2E,6E)-farnesyl diphosphate + dansyl-GCVLS
dansyl-G-(S-(2E,6E)-farnesyl)CVLS + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + K Ras-cysteine
S-(2E,6E)-farnesyl-[K Ras]-L-cysteine + diphosphate
-
-
-
?
(2E,6E)-farnesyl diphosphate + KGCVIM
S-(2E,6E)-farnesyl-KGCVIM + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + KGCVVM
S-(2E,6E)-farnesyl-KGCVVM + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + [H Ras]-L-cysteine
S-(2E,6E)-farnesyl-[H Ras]-L-cysteine + diphosphate
(2E,6E)-farnesyl diphosphate + [K Ras]-L-cysteine
S-(2E,6E)-farnesyl-[K Ras]-L-cysteine + diphosphate
(2E,6E)-farnesyl diphosphate + [N Ras]-L-cysteine
S-(2E,6E)-farnesyl-[N Ras]-L-cysteine + diphosphate
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
[protein]-S-((2E,6E)-farnesyl)-L-cysteine + diphosphate
-
assay at pH 7.5, 30°C
-
-
?
(2E,6E)-farnesyl diphosphate + [Rho]-L-cysteine
S-(2E,6E)-farnesyl-[Rho]-L-cysteine + diphosphate
(2E,6E,10E)-3,7,11-trimethyl-12-(prop-2-yn-1-yloxy)dodeca-2,6,10-trien-1-yl diphosphate + CCIQ
?
-
-
-
-
?
(2E,6E,10E)-3,7,11-trimethyl-12-(prop-2-yn-1-yloxy)dodeca-2,6,10-trien-1-yl diphosphate + CGGDD
?
-
-
-
-
?
(2E,6E,10E)-3,7,11-trimethyl-12-(prop-2-yn-1-yloxy)dodeca-2,6,10-trien-1-yl diphosphate + CSVL
?
-
-
-
-
?
(2E,6E,10E)-3,7,11-trimethyl-12-(prop-2-yn-1-yloxy)dodeca-2,6,10-trien-1-yl diphosphate + CTIQ
?
-
-
-
-
?
(2E,6E,10E)-3,7,11-trimethyl-12-(prop-2-yn-1-yloxy)dodeca-2,6,10-trien-1-yl diphosphate + CVIS
?
-
-
-
-
?
(2E,6E,10E)-3,7,11-trimethyl-12-(prop-2-yn-1-yloxy)dodeca-2,6,10-trien-1-yl diphosphate + CVLL
?
-
-
-
-
?
(2E,6E,10E)-3,7,11-trimethyl-12-(prop-2-yn-1-yloxy)dodeca-2,6,10-trien-1-yl diphosphate + CVLS
?
-
-
-
-
?
(2E,6Z)-3,11-dimethyl-7-(prop-2-yn-1-yl)dodeca-2,6,10-trien-1-yl diphosphate + CCIQ
?
-
-
-
-
?
(2E,6Z)-3,11-dimethyl-7-(prop-2-yn-1-yl)dodeca-2,6,10-trien-1-yl diphosphate + CGGDD
?
-
-
-
-
?
(2E,6Z)-3,11-dimethyl-7-(prop-2-yn-1-yl)dodeca-2,6,10-trien-1-yl diphosphate + CSVL
?
-
-
-
-
?
(2E,6Z)-3,11-dimethyl-7-(prop-2-yn-1-yl)dodeca-2,6,10-trien-1-yl diphosphate + CTIQ
?
-
-
-
-
?
(2E,6Z)-3,11-dimethyl-7-(prop-2-yn-1-yl)dodeca-2,6,10-trien-1-yl diphosphate + CVIS
?
-
-
-
-
?
(2E,6Z)-3,11-dimethyl-7-(prop-2-yn-1-yl)dodeca-2,6,10-trien-1-yl diphosphate + CVLL
?
-
-
-
-
?
(2E,6Z)-3,11-dimethyl-7-(prop-2-yn-1-yl)dodeca-2,6,10-trien-1-yl diphosphate + CVLS
?
-
-
-
-
?
(2E,6Z)-7-(but-3-yn-1-yl)-3,11-dimethyldodeca-2,6,10-trien-1-yl diphosphate + CCIQ
?
-
-
-
-
?
(2E,6Z)-7-(but-3-yn-1-yl)-3,11-dimethyldodeca-2,6,10-trien-1-yl diphosphate + CGGDD
?
-
-
-
-
?
(2E,6Z)-7-(but-3-yn-1-yl)-3,11-dimethyldodeca-2,6,10-trien-1-yl diphosphate + CSVL
?
-
-
-
-
?
(2E,6Z)-7-(but-3-yn-1-yl)-3,11-dimethyldodeca-2,6,10-trien-1-yl diphosphate + CTIQ
?
-
-
-
-
?
(2E,6Z)-7-(but-3-yn-1-yl)-3,11-dimethyldodeca-2,6,10-trien-1-yl diphosphate + CVIS
?
-
-
-
-
?
(2E,6Z)-7-(but-3-yn-1-yl)-3,11-dimethyldodeca-2,6,10-trien-1-yl diphosphate + CVLL
?
-
-
-
-
?
(2E,6Z)-7-(but-3-yn-1-yl)-3,11-dimethyldodeca-2,6,10-trien-1-yl diphosphate + CVLS
?
-
-
-
-
?
(2Z)-geranylgeranyl diphosphate + protein cysteine
diphosphate + S-(2Z)-geranylgeranylcysteinyl protein
-
-
-
-
?
10-benzyloxy-3-methyl-2-decen-1-ol-diphosphate + N-dansyl-Gly-Cys-Val-Leu-Ser
diphosphate + N-dansyl-Gly-S-(10-benzyloxy-3-methyl-2-decenyl)-Cys-Val-Leu-Ser
-
-
-
-
?
12-propargoxyfarnesyl diphosphate + N-dansyl-Gly-Cys-Val-Ile-Ala-OH
diphosphate + propargoxyfarnesyl N-dansyl-Gly-Cys-Val-Ile-Ala-OH
-
-
-
-
?
3-(3-methyl-2-butenyl)-7,11-dimethyldodeca-2(Z),6(E),10-triene 1-diphosphate + dansyl-Gly-Cys-Lys-Thr-Gln
? + diphosphate
-
-
-
-
?
3-(3-methyl-2-butenyl)-7,11-dimethyldodeca-2(Z),6(E),10-triene 1-diphosphate + dansyl-Gly-Cys-Lys-Val-Leu
? + diphosphate
-
-
-
-
?
3-(3-methyl-2-butenyl)-7,11-dimethyldodeca-2(Z),6(E),10-triene 1-diphosphate + dansyl-Gly-Cys-Val-Ile-Met
? + diphosphate
-
-
-
-
?
3-(3-methyl-2-butenyl)-7,11-dimethyldodeca-2(Z),6(E),10-triene 1-diphosphate + dansyl-Gly-Cys-Val-Leu-Ser
? + diphosphate
-
-
-
-
?
3-(azidomethyl)-N-[(2E,6E,8E)-2,6-dimethyl-8-(oxodiphosphanylidene)octa-2,6-dien-1-yl]aniline + protein-cysteine
?
-
-
-
-
?
3-(azidomethyl)-N-[(4E,8E,10E)-4,8-dimethyl-10-(oxodiphosphanylidene)deca-4,8-dien-1-yl]aniline + protein-cysteine
?
-
-
-
-
?
6-benzyloxy-3-methyl-2-hexen-1-ol-diphosphate + N-dansyl-Gly-Cys-Val-Leu-Ser
diphosphate + N-dansyl-Gly-S-(6-benzyloxy-3-methyl-2-hexenyl)-Cys-Val-Leu-Ser
-
-
-
-
?
7-benzyloxy-3-methyl-2-hepten-1-ol-diphosphate + N-dansyl-Gly-Cys-Val-Leu-Ser
diphosphate + N-dansyl-Gly-S-(7-benzyloxy-3-methyl-2-heptenyl)-Cys-Val-Leu-Ser
-
-
-
-
?
8-benzyloxy-3-methyl-2-octen-1-ol-diphosphate + N-dansyl-Gly-Cys-Val-Leu-Ser
diphosphate + N-dansyl-Gly-S-(8-benzyloxy-3-methyl-2-octenyl)-Cys-Val-Leu-Ser
-
-
-
-
?
9-benzyloxy-3-methyl-2-nonen-1-ol-diphosphate + N-dansyl-Gly-Cys-Val-Leu-Ser
diphosphate + N-dansyl-Gly-S-(9-benzyloxy-3-methyl-2-nonenyl)-Cys-Val-Leu-Ser
-
-
-
-
?
CALQ + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CALQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CALV + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CALV + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CAVQ + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CAVQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CCIF + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CCIF + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CCIL + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CCIL + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CDVK + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CDVK + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CEIQ + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CEIQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CFLS + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CFLS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CFPS + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CFPS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CFTN + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CFTN + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CFVN + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CFVN + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CGIA + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CGIA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CGIM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CGIM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CGLF + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CGLF + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CGLY + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CGLY + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CGVV + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CGVV + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CHIM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CHIM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CHIQ + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CHIQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CHLM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CHLM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CHLS + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CHLS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CHVM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CHVM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CHVQ + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CHVQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CIVA + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CIVA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CKIF + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CKIF + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CKIS + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CKIS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CKIV + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CKIV + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CLIT + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CLIT + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CLLM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CLLM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CLLV + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CLLV + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CLML + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CLML + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CLTS + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CLTS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CLVM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CLVM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CNIM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CNIM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CNLF + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CNLF + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CNLK + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CNLK + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CNLM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CNLM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CNLQ + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CNLQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CQTA + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CQTA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CRIS + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CRIS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CSFM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CSFM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CSIM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CSIM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CSIS + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CSIS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CSLA + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CSLA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CSLC + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CSLC + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CSLG + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CSLG + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CSLH + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CSLH + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CSLM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CSLM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CSVQ + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CSVQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CSVS + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CSVS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CTII + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CTII + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CTIV + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CTIV + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CTKF + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CTKF + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CTLA + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CTLA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CTLM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CTLM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CTLQ + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CTLQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CTMS + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CTMS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CTTQ + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CTTQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CTVF + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CTVF + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CTVS + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CTVS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CTVV + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CTVV + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CVHF + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CVHF + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CVLA + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CVLA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CVLH + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CVLH + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CVLQ + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CVLQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CVQM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CVQM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CVVT + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CVVT + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CYIS + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CYIS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CYLA + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CYLA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CYPD + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CYPD + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
CYVM + (2E,6E)-farnesyl diphosphate
S-(2E,6E)-farnesyl-CYVM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVAA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVAA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVAM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVAM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVAQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVAQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVAS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVAS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVCA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVCA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVCM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVCM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVCQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVCQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVCS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVCS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVDA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVDA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVDM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVDM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVDQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVDQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVDS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVDS + diphosphate
dansyl-GCVEA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVEA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVEM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVEM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVEQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVEQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVES + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVES + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVFA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVFA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVFM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVFM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVFQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVFQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVFS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVFS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVGA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVGA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVGM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVGM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVGQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVGQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVGS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVGS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVHA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVHA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVHM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVHM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVHQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVHQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVHS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVHS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVIA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVIA + diphosphate
dansyl-GCVIA + 1-(4,5-dimethoxy-nitrophenyl)ethyl (2E,6E)-farnesyl diphosphate
?
-
7.6% enzyme activity, specific activity 0.058 microM/min
-
-
?
dansyl-GCVIA + 2-nitrophenyl (2E,6E)-farnesyl diphosphate
?
-
14% enzyme activity, specific activity 0.104 microM/min
-
-
?
dansyl-GCVIM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVIM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVIQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVIQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVIS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVIS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVKA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVKA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVKLQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVLQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVKM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVKM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVKQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVKQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVKS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVKS + diphosphate
dansyl-GCVLA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVLA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVLM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVLM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVLS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVLS + diphosphate
dansyl-GCVLS + (E)-[4-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]phenyl]-methanyl diphosphate
dansyl-G-(S-(E)-[4-[(3,7-dimethylocta-2,6-dien-1-yl)oxy]phenyl]-methanyl)CVLS + diphosphate
-
-
-
-
?
dansyl-GCVLS + [3-[(3-phenoxyphenoxy)methyl]phenyl]-methanyl diphosphate
dansyl-G-(S-[3-[(3-phenoxyphenoxy)methyl]phenyl]-methanyl)CVLS + diphosphate
-
-
-
-
?
dansyl-GCVMA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVMA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVMM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVMM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVMQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVMQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVMS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVMS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVNA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVNA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVNM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVNM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVNQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVNQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVNS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVNS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVPA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVPA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVPM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVPM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVPQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVPQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVPS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVPS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVQA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVQA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVQM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVQM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVQQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVQQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVQs + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVQS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVSA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVSA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVSM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVSM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVSQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVSQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVSS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVSS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVTA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVTA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVTM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVTM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVTQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVTQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVTS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVTS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVVA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVVA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVVM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVVM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVVQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVVQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVVS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVVS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVWA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVWA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVWM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVWM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVWQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVWQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVWS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVWS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVYA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVYA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVYM + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVYM + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVYQ + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVYQ + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVYS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVYS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
farnesyl diphosphate + dansyl-GCVLS
diphosphate + S-farnesyl dansyl-GCVLS
-
-
-
-
?
farnesyl diphosphate + dansyl-Gly-Cys-Lys-Thr-Gln
dansyl-Gly-S-farnesyl-Cys-Lys-Thr-Gln + diphosphate
-
-
-
-
?
farnesyl diphosphate + dansyl-Gly-Cys-Lys-Val-Leu
dansyl-Gly-S-farnesyl-Cys-Lys-Val-Leu + diphosphate
-
-
-
-
?
farnesyl diphosphate + dansyl-Gly-Cys-Val-Ile-Met
dansyl-Gly-S-farnesyl-Cys-Val-Ile-Met + diphosphate
-
-
-
-
?
farnesyl diphosphate + dansyl-Gly-Cys-Val-Leu-Ser
dansyl-Gly-S-farnesyl-Cys-Val-Leu-Ser + diphosphate
-
-
-
-
?
farnesyl diphosphate + GCVLS
Gly-S-farnesyl-Cys-Val-Leu-Ser + diphosphate
-
-
-
-
?
farnesyl diphosphate + GST-CIIL
diphosphate + S-farnesyl-GST-Cys-Ile-Ile-Ser
-
-
-
-
?
farnesyl diphosphate + GST-Cys-Ile-Ile-Ser
diphosphate + S-farnesyl-GST-Cys-Ile-Ile-Ser
-
-
-
-
?
farnesyl diphosphate + human recombinant wild-type H-Ras-CVLS
diphosphate + ?
-
-
-
?
farnesyl diphosphate + mutant H-Ras-CVLL
diphosphate + ?
20fold less active than human recombinant wild-type H-Ras-CVLS
-
-
-
farnesyl diphosphate + N-dansyl-Gly-Cys-Val-Leu-Ser
diphosphate + N-dansyl-Gly-S-farnesyl-Cys-Val-Leu-Ser
-
the best substrate
-
-
?
farnesyl diphosphate + Ras oncoprotein p21
diphosphate + Ras-S-farnesyl oncoprotein p21
-
-
-
-
?
farnesyl diphosphate + Ras protein
diphosphate + S-farnesyl Ras protein
-
-
-
-
?
farnesyl diphosphate + Ras-Cys-Val-Leu-Met
diphosphate + Ras-S-farnesyl-Cys-Val-Leu-Met
-
-
-
-
?
farnesyl diphosphate + Thr-Lys-Cys-Val-Ile-Leu
Thr-Lys-S-farnesyl-Cys-Val-Ile-Leu + diphosphate
-
-
-
-
?
farnesyl diphosphate + Thr-Lys-Cys-Val-Ile-Met
Thr-Lys-S-farnesyl-Cys-Val-Ile-Met + diphosphate
-
-
-
-
?
farnesyl diphosphate + Thr-Lys-Cys-Val-Ile-Phe
Thr-Lys-S-farnesyl-Cys-Val-Ile-Phe + diphosphate
-
-
-
-
?
farnesyl diphosphate + Thr-Lys-Cys-Val-Ile-Ser
Thr-Lys-S-farnesyl-Cys-Val-Ile-Ser + diphosphate
-
-
-
-
?
farnesyl diphosphate + Thr-Lys-Cys-Val-Leu-Ala
Thr-Lys-S-farnesyl-Cys-Val-Leu-Ala + diphosphate
-
-
-
-
?
farnesyl diphosphate + [protein]-L-cysteine
[protein]-S-((2E,6E)-farnesyl)-L-cysteine + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
farnesyl monophosphate + Gly-Cys-Val-Leu-Ser
phosphate + Gly-S-farnesyl-Cys-Val-Leu-Ser
-
-
-
-
?
farnesyl triphosphate + Ras-Cys-Val-Ile-Met
triphosphate + Ras-S-farnesyl-Cys-Val-Ile-Met
-
-
-
-
?
geranyl alkyne diphosphate + N-dansyl-GCVIA
N-dansyl-G-(alkyne geranyl)CVIA + diphosphate
-
-
-
-
ir
geranyl diphosphate + dansyl-GCVLS
dansyl-G-(S-geranyl)CVLS + diphosphate
-
-
-
-
?
geranylgeranyl diphosphate + N-dansyl-Gly-Cys-Val-Leu-Ser
diphosphate + N-dansyl-Gly-S-geranylgeranyl-Cys-Val-Leu-Ser
-
-
-
-
?
geranylgeranyl diphosphate + protein-cysteine
diphosphate + S-geranylgeranylcysteinyl protein
-
-
-
-
?
YRASNRSCAIM + farnesyl diphosphate
YRASNRS-(S-farnesyl)CAIM + diphosphate
-
-
-
-
?
[(4E,8E,10E)-4,8-dimethyl-10-(oxodiphosphanylidene)deca-4,8-dien-1-yl]oxyacetonitrile + protein-cysteine
?
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + (protein)-L-cysteine
S-(2E,6E)-farnesyl protein + diphosphate
-
-
-
?
(2E,6E)-farnesyl diphosphate + (protein)-L-cysteine
S-(2E,6E)-farnesyl protein + diphosphate
Q04631 AND Q02293
-
-
-
?
(2E,6E)-farnesyl diphosphate + (protein)-L-cysteine
S-(2E,6E)-farnesyl protein + diphosphate
P29703 AND P22007
-
-
-
?
(2E,6E)-farnesyl diphosphate + [H Ras]-L-cysteine
S-(2E,6E)-farnesyl-[H Ras]-L-cysteine + diphosphate
-
-
-
?
(2E,6E)-farnesyl diphosphate + [H Ras]-L-cysteine
S-(2E,6E)-farnesyl-[H Ras]-L-cysteine + diphosphate
-
-
-
?
(2E,6E)-farnesyl diphosphate + [K Ras]-L-cysteine
S-(2E,6E)-farnesyl-[K Ras]-L-cysteine + diphosphate
-
-
-
?
(2E,6E)-farnesyl diphosphate + [K Ras]-L-cysteine
S-(2E,6E)-farnesyl-[K Ras]-L-cysteine + diphosphate
-
-
-
?
(2E,6E)-farnesyl diphosphate + [N Ras]-L-cysteine
S-(2E,6E)-farnesyl-[N Ras]-L-cysteine + diphosphate
-
-
-
?
(2E,6E)-farnesyl diphosphate + [N Ras]-L-cysteine
S-(2E,6E)-farnesyl-[N Ras]-L-cysteine + diphosphate
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
-
the reaction is catalyzed by protein farnesyltransferase on protein substrates bearing the C-terminal CaaX motif
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
Q9Y765 AND A0A0A6KLS8
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + [Rho]-L-cysteine
S-(2E,6E)-farnesyl-[Rho]-L-cysteine + diphosphate
-
-
-
?
(2E,6E)-farnesyl diphosphate + [Rho]-L-cysteine
S-(2E,6E)-farnesyl-[Rho]-L-cysteine + diphosphate
-
-
-
?
dansyl-GCVDS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVDS + diphosphate
-
poor substrate for wild-type
-
-
?
dansyl-GCVDS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVDS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVIA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVIA + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVIA + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVIA + diphosphate
-
100% enzyme activity, specific activity 0.765 microM/min
-
-
?
dansyl-GCVKS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVKS + diphosphate
-
poor substrate for wild-type
-
-
?
dansyl-GCVKS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVKS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
dansyl-GCVLS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVLS + diphosphate
-
-
-
-
?
dansyl-GCVLS + (2E,6E)-farnesyl diphosphate
dansyl-G-(S-(2E,6E)-farnesyl)CVLS + diphosphate
-
assay at pH 7.8, 25°C
-
-
?
farnesyl diphosphate + biotin-YRASNRSCAIM
diphosphate + biotin-YRASNRS-(S-farnesyl)CAIM
-
-
-
-
?
farnesyl diphosphate + biotin-YRASNRSCAIM
diphosphate + biotin-YRASNRS-(S-farnesyl)CAIM
-
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
posttranslational lipid modification in which a 15-carbon farnesyl isoprenoid is linked via a thioether bond to specific cysteine residues of proteins, the reactive cysteine is located in the C-terminal Ca1a2X motif in which C is the modified cysteine, a1 and a2 are often an aliphatic residue, and X is Ser, Met, Ala or Gln
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
substrate: Ras-CVIM and GST-PEP
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
Q6EZ49
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
-
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
-
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
-
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
-
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
-
ir
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
Ftase has an autonomous recognition sequence, referred to as the CAAX box, where C is a cysteine, A is usually an aliphatic amino acid, and X can be a variety of amino acids
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
Q8WR00, Q8WR01
enzyme prefers Gln and Met at the X position but not Ser, Thr or Cys, which are good substrates for mammalian enzyme
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
posttranslational lipid modification in which a 15-carbon farnesyl isoprenoid is linked via a thioether bond to specific cysteine residues of proteins, the reactive cysteine is located in the C-terminal Ca1a2X motif in which C is the modified cysteine, a1 and a2 are often an aliphatic residue, and X is Ser, Met, Ala or Gln
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
prenylation, farnesylation, substrates are Ras, nuclear lamins, transducin gamma subunit, protein substrate motif: Cys-aliphatic-aliphatic-X, X: M, S, Q, A, F
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
posttranslational lipid modification in which a 15-carbon farnesyl isoprenoid is linked via a thioether bond to specific cysteine residues of proteins, the reactive cysteine is located in the C-terminal Ca1a2X motif in which C is the modified cysteine, a1 and a2 are often an aliphatic residue, and X is Ser, Met, Ala or Gln
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
posttranslational lipid modification in which a 15-carbon farnesyl isoprenoid is linked via a thioether bond to specific cysteine residues of proteins, the reactive cysteine is located in the C-terminal Ca1a2X motif in which C is the modified cysteine, a1 and a2 are often an aliphatic residue, and X is Ser, Met, Ala or Gln
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
posttranslational lipid modification in which a 15-carbon farnesyl isoprenoid is linked via a thioether bond to specific cysteine residues of proteins, the reactive cysteine is located in the C-terminal Ca1a2X motif in which C is the modified cysteine, a1 and a2 are often an aliphatic residue, and X is Ser, Met, Ala or Gln
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
posttranslational lipid modification in which a 15-carbon farnesyl isoprenoid is linked via a thioether bond to specific cysteine residues of proteins, the reactive cysteine is located in the C-terminal Ca1a2X motif in which C is the modified cysteine, a1 and a2 are often an aliphatic residue, and X is Ser, Met, Ala or Gln
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
posttranslational lipid modification in which a 15-carbon farnesyl isoprenoid is linked via a thioether bond to specific cysteine residues of proteins, the reactive cysteine is located in the C-terminal Ca1a2X motif in which C is the modified cysteine, a1 and a2 are often an aliphatic residue, and X is Ser, Met, Ala or Gln
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
posttranslational lipid modification in which a 15-carbon farnesyl isoprenoid is linked via a thioether bond to specific cysteine residues of proteins, the reactive cysteine is located in the C-terminal Ca1a2X motif in which C is the modified cysteine, a1 and a2 are often an aliphatic residue, and X is Ser, Met, Ala or Gln
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
posttranslational lipid modification in which a 15-carbon farnesyl isoprenoid is linked via a thioether bond to specific cysteine residues of proteins, the reactive cysteine is located in the C-terminal Ca1a2X motif in which C is the modified cysteine, a1 and a2 are often an aliphatic residue, and X is Ser, Met, Ala or Gln
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
Ha-Ras-CVLS, which is a good substrate for mammalian enzyme, not farnesylated by the parasite enzyme, only the mammalian enzyme substrate RAS1-CVIM farnesylated by parasite enzyme
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
substrate are: Ras superfamiliy and Ras-related proteins for example Rap, Rab, Rac and Ral, large G proteins, nuclear lamins, rhodopsin kinase and the retinal cGMP phosphodiesterase
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
substrate are: Ras superfamiliy and Ras-related proteins for example Rap, Rab, Rac and Ral, large G proteins, nuclear lamins, rhodopsin kinase and the retinal cGMP phosphodiesterase
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
enzyme prefers linear residues in the X position of the CaaX box over branched residues, enzyme prefers Gln, Met and Ser at the X position
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
substrates are cellular proteins such as Ras at a cysteine residue near their carboxy-terminus
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
prenylation, farnesylation, substrates are Ras, nuclear lamins, transducin gamma subunit, protein substrate motif: Cys-aliphatic-aliphatic-X, X: M, S, Q, A, F
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
prenylation, farnesylation, substrates are Ras, nuclear lamins, transducin gamma subunit, protein substrate motif: Cys-aliphatic-aliphatic-X, X: M, S, Q, A, F
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
prenylation, farnesylation, substrates are Ras, nuclear lamins, transducin gamma subunit, protein substrate motif: Cys-aliphatic-aliphatic-X, X: M, S, Q, A, F
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
prenylation, farnesylation, substrates are Ras, nuclear lamins, transducin gamma subunit, protein substrate motif: Cys-aliphatic-aliphatic-X, X: M, S, Q, A, F
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
prenylation, farnesylation, substrates are Ras, nuclear lamins, transducin gamma subunit, protein substrate motif: Cys-aliphatic-aliphatic-X, X: M, S, Q, A, F
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
prenylation, farnesylation, substrates are Ras, nuclear lamins, transducin gamma subunit, protein substrate motif: Cys-aliphatic-aliphatic-X, X: M, S, Q, A, F
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
prenylation, farnesylation, substrates are Ras, nuclear lamins, transducin gamma subunit, protein substrate motif: Cys-aliphatic-aliphatic-X, X: M, S, Q, A, F
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
prenylation, farnesylation, substrates are Ras, nuclear lamins, transducin gamma subunit, protein substrate motif: Cys-aliphatic-aliphatic-X, X: M, S, Q, A, F
-
ir
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
preferred CaaX-substrate: CAIM
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
prenylation, farnesylation, substrates are Ras, nuclear lamins, transducin gamma subunit, protein substrate motif: Cys-aliphatic-aliphatic-X, X: M, S, Q, A, F
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
prenylation, farnesylation, substrates are Ras, nuclear lamins, transducin gamma subunit, protein substrate motif: Cys-aliphatic-aliphatic-X, X: M, S, Q, A, F
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
preferred CaaX-substrate: CAIM
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
the specific CAQQ motif of the ANJ1 protein has a low affinity for enzyme in vitro, enzyme specifically farnesylated the RasB-CVIM peptide substrate
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
substrate: Biotin lamin-B protein
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
Ha-Ras-CVLS, which is a good substrate for mammalian enzyme, not farnesylated by the parasite enzyme, only the mammalian enzyme substrate RAS1-CVIM farnesylated by parasite enzyme
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
enzyme prefers Gln and Met at the X position but not Ser, Thr or Cys, which are good substrates for mammalian enzyme
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
enzyme prefers Gln and Met at the X position but not Ser, Thr or Cys, which are good substrates for mammalian enzyme
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
Ha-Ras-CVLS, which is a good substrate for mammalian enzyme, not farnesylated by the parasite enzyme, only the mammalian enzyme substrate RAS1-CVIM farnesylated by parasite enzyme
-
?
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
enzyme prefers Gln and Met at the X position but not Ser, Thr or Cys, which are good substrates for mammalian enzyme
-
?
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
-
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process required for the transforming activity of oncogenic variants of Ras, making enzyme a prime target for anticancer therapeutics
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process necessary for the subcellular localisation of substrate to the plasma membrane
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
the enzyme catalyzes posttranslational modification of proteins, the farnesyl moieties attached to the substrates are direcly involved in protein-protein interactions as well as in protein-membrane interactions
-
-
?
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
substrate motif: carboxy-terminal -Ca1a2X box
-
-
?
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
protein farnesylation is essential for early embryonic proliferation but dispensable for postnatal development and adult homeostasis. Ablation of FTase during tumor progression results in significant tumor reduction
-
-
?
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
potential role for plant enzyme in cell cycle regulation
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
potential role for plant enzyme in cell cycle regulation
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
potential role for cell cycle
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
-
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
-
-
-
?
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process required for the transforming activity of oncogenic variants of Ras, making enzyme a prime target for anticancer therapeutics
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process necessary for the subcellular localisation of substrate to the plasma membrane
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
enzyme responsible for catalysing isoprene lipid modifications
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
A series of steps modifies the C-terminus of Ras. Enzyme catalyses the first of these steps by transferring the farnesyl group from farnesyl diphosphates to the cysteine side chain in the CAAX sequence motif at the C-terminus of Ras
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
catalyzes the post-translational modification of many important cellular proteins
-
-
?
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
-
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process required for the transforming activity of oncogenic variants of Ras, making enzyme a prime target for anticancer therapeutics
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process necessary for the subcellular localisation of substrate to the plasma membrane
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
a possible role for the enzyme during fruit development
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
enzyme responsible for catalysing isoprene lipid modifications
-
-
-
farnesyl diphosphate + Ras-Cys-Val-Ile-Met
diphosphate + Ras-S-farnesyl-Cys-Val-Ile-Met
-
-
-
-
?
farnesyl diphosphate + Ras-Cys-Val-Ile-Met
diphosphate + Ras-S-farnesyl-Cys-Val-Ile-Met
-
-
-
-
?
farnesyl diphosphate + Ras-Cys-Val-Ile-Met
diphosphate + Ras-S-farnesyl-Cys-Val-Ile-Met
-
-
-
-
?
farnesyl diphosphate + Ras-Cys-Val-Ile-Met
diphosphate + Ras-S-farnesyl-Cys-Val-Ile-Met
-
best substrate
-
-
?
farnesyl diphosphate + Ras-Cys-Val-Ile-Met
diphosphate + Ras-S-farnesyl-Cys-Val-Ile-Met
-
best substrate
-
-
?
farnesyl diphosphate + Ras-Cys-Val-Ile-Met
diphosphate + Ras-S-farnesyl-Cys-Val-Ile-Met
-
-
-
-
?
farnesyl diphosphate + Ras-Cys-Val-Ile-Met
diphosphate + Ras-S-farnesyl-Cys-Val-Ile-Met
-
-
-
-
?
additional information
?
-
Q9Y765 AND A0A0A6KLS8
protein farnesytransferase catalyzes the farnesylation of proteins with a C-terminal tetrapeptide sequence denoted as a Ca1a2X box, determination of substrate recognition sequences, and substrate specificity, screening of the CVa2X library with alkyne-functionalized isoprenoid substrates, detailed overview
-
-
-
additional information
?
-
-
biotin-GPP is not transferred to the peptide substrate to any measurable extent
-
-
-
additional information
?
-
FTase-I can transfer isoprenoids to intracellular proteins that contain CAAX motifs. The isoprenoid groups can be selectively recognized by GGTase-I. The 15-carbon isoprenoid geranylgeranyl from its donor farnesyldiphosphate (FPP) is specific to FTase-I. Residues Lysalpha164, Hisbeta248, Argbeta291 and Tyrbeta300 in FTase can form hydrogen bonds with farnesyl diphosphate. When FTase is inhibited by a FTI, N-Ras and K-Ras can be alternatively prenylated by GGTase-I, EC 2.5.1.59, but H-Ras cannot
-
-
-
additional information
?
-
FTase-I can transfer isoprenoids to intracellular proteins that contain CAAX motifs. The isoprenoid groups can be selectively recognized by GGTase-I. The 15-carbon isoprenoid geranylgeranyl from its donor farnesyldiphosphate (FPP) is specific to FTase-I. Residues Lysalpha164, Hisbeta248, Argbeta291 and Tyrbeta300 in FTase can form hydrogen bonds with farnesyl diphosphate. When FTase is inhibited by a FTI, N-Ras and K-Ras can be alternatively prenylated by GGTase-I, EC 2.5.1.59, but H-Ras cannot
-
-
-
additional information
?
-
-
enzyme-substrate interaction study using synthetic peptides as substrates, modelling of the enyzme interaction with substrate protein tyrosine phosphatase, protein-protein docking and molecular dynamics simulation, overview
-
-
-
additional information
?
-
-
although farnesyl diphosphate and geranylgeranyl diphosphate bind competitively, the geranyl geranyl diphosphate is not transferred efficiently to the protein substrate by enzyme
-
-
-
additional information
?
-
-
steady-state kinetics for modification of peptide substrates shows that the multiple-turnover activity depends on the analogue structure. Analogues in which the first isoprene is replaced with a benzyl group and an analogue in which each isoprene is replaced with an aryl group are good substrates. The single-turnover rate constant for alkylation depends on the Ca1a2X peptide sequence. The isoprenoid transition-state conformation is preferred over the inactive E-FPP-Ca1a2X ternary complex conformation and the farnesyl binding site in the exit groove may be significantly more selective for the farnesyl diphosphate substrate than the active site binding pocket
-
-
-
additional information
?
-
ligand interaction analysis with FTase alpha subunit, mass spectrometry, overview. The enzyme alpha-subunit interacts with Vps4A protein in vitro and in vivo
-
-
-
additional information
?
-
-
analogues of farnesyl diphosphate alter CaaX substrate specificity and reactions rates of protein farnesyltransferase, reactivity of four alkyne-containing analogs of farnesyl diphosphate with purified protein farnesyltransferase and a small library of dansylated peptides using an in vitro continuous spectrofluorimetric assay, overview. Activity with CGGDD, CVLL, and CSVL peptides is low with farnesyl diphosphate as well as with its analogues
-
-
-
additional information
?
-
FTase-I can transfer isoprenoids to intracellular proteins that contain CAAX motifs. The isoprenoid groups can be selectively recognized by GGTase-I. The 15-carbon isoprenoid geranylgeranyl from its donor farnesyldiphosphate (FPP) is specific to FTase-I. Residues Lysalpha164, Hisbeta248, Argbeta291 and Tyrbeta300 in FTase can form hydrogen bonds with farnesyl diphosphate. When FTase is inhibited by a FTI, N-Ras and K-Ras can be alternatively prenylated by GGTase-I, EC 2.5.1.59, but H-Ras cannot
-
-
-
additional information
?
-
FTase-I can transfer isoprenoids to intracellular proteins that contain CAAX motifs. The isoprenoid groups can be selectively recognized by GGTase-I. The 15-carbon isoprenoid geranylgeranyl from its donor farnesyldiphosphate (FPP) is specific to FTase-I. Residues Lysalpha164, Hisbeta248, Argbeta291 and Tyrbeta300 in FTase can form hydrogen bonds with farnesyl diphosphate. When FTase is inhibited by a FTI, N-Ras and K-Ras can be alternatively prenylated by GGTase-I, EC 2.5.1.59, but H-Ras cannot
-
-
-
additional information
?
-
Q04631 AND Q02293
protein farnesytransferase catalyzes the farnesylation of proteins with a C-terminal tetrapeptide sequence denoted as a Ca1a2X box, determination of substrate recognition sequences, and substrate specificity, screening of the CVa2X library with alkyne-functionalized isoprenoid substrates, detailed overview
-
-
-
additional information
?
-
-
protein farnesytransferase catalyzes the farnesylation of proteins with a C-terminal tetrapeptide sequence denoted as a Ca1a2X box, determination of substrate recognition sequences, and substrate specificity, screening of the CVa2X library with alkyne-functionalized isoprenoid substrates, detailed overview
-
-
-
additional information
?
-
ligand interaction analysis with FTase alpha subunit, mass spectrometry, overview. The enzyme alpha-subunit interacts with Vps4A protein in vitro and in vivo
-
-
-
additional information
?
-
P29703 AND P22007
protein farnesytransferase catalyzes the farnesylation of proteins with a C-terminal tetrapeptide sequence denoted as a Ca1a2X box, determination of substrate recognition sequences, and substrate specificity, screening of the CVa2X library with alkyne-functionalized isoprenoid substrates, detailed overview
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(2E,6E)-farnesyl diphosphate + (protein)-L-cysteine
S-(2E,6E)-farnesyl protein + diphosphate
(2E,6E)-farnesyl diphosphate + [H Ras]-L-cysteine
S-(2E,6E)-farnesyl-[H Ras]-L-cysteine + diphosphate
(2E,6E)-farnesyl diphosphate + [K Ras]-L-cysteine
S-(2E,6E)-farnesyl-[K Ras]-L-cysteine + diphosphate
(2E,6E)-farnesyl diphosphate + [N Ras]-L-cysteine
S-(2E,6E)-farnesyl-[N Ras]-L-cysteine + diphosphate
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
(2E,6E)-farnesyl diphosphate + [Rho]-L-cysteine
S-(2E,6E)-farnesyl-[Rho]-L-cysteine + diphosphate
farnesyl diphosphate + protein-cysteine
diphosphate + S-farnesyl protein
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + (protein)-L-cysteine
S-(2E,6E)-farnesyl protein + diphosphate
P49354, P49356
-
-
-
?
(2E,6E)-farnesyl diphosphate + (protein)-L-cysteine
S-(2E,6E)-farnesyl protein + diphosphate
Q04631 AND Q02293
-
-
-
?
(2E,6E)-farnesyl diphosphate + (protein)-L-cysteine
S-(2E,6E)-farnesyl protein + diphosphate
P29703 AND P22007
-
-
-
?
(2E,6E)-farnesyl diphosphate + [H Ras]-L-cysteine
S-(2E,6E)-farnesyl-[H Ras]-L-cysteine + diphosphate
P49354, P49356
-
-
-
?
(2E,6E)-farnesyl diphosphate + [H Ras]-L-cysteine
S-(2E,6E)-farnesyl-[H Ras]-L-cysteine + diphosphate
Q02293, Q04631
-
-
-
?
(2E,6E)-farnesyl diphosphate + [K Ras]-L-cysteine
S-(2E,6E)-farnesyl-[K Ras]-L-cysteine + diphosphate
P49354, P49356
-
-
-
?
(2E,6E)-farnesyl diphosphate + [K Ras]-L-cysteine
S-(2E,6E)-farnesyl-[K Ras]-L-cysteine + diphosphate
Q02293, Q04631
-
-
-
?
(2E,6E)-farnesyl diphosphate + [N Ras]-L-cysteine
S-(2E,6E)-farnesyl-[N Ras]-L-cysteine + diphosphate
P49354, P49356
-
-
-
?
(2E,6E)-farnesyl diphosphate + [N Ras]-L-cysteine
S-(2E,6E)-farnesyl-[N Ras]-L-cysteine + diphosphate
Q02293, Q04631
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
Q9Y765 AND A0A0A6KLS8
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
P49354, P49356
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
Q02293, Q04631
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + [protein]-L-cysteine
S-(2E,6E)-farnesyl-[protein]-L-cysteine + diphosphate
-
-
-
-
?
(2E,6E)-farnesyl diphosphate + [Rho]-L-cysteine
S-(2E,6E)-farnesyl-[Rho]-L-cysteine + diphosphate
P49354, P49356
-
-
-
?
(2E,6E)-farnesyl diphosphate + [Rho]-L-cysteine
S-(2E,6E)-farnesyl-[Rho]-L-cysteine + diphosphate
Q02293, Q04631
-
-
-
?
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
-
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process required for the transforming activity of oncogenic variants of Ras, making enzyme a prime target for anticancer therapeutics
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process necessary for the subcellular localisation of substrate to the plasma membrane
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
the enzyme catalyzes posttranslational modification of proteins, the farnesyl moieties attached to the substrates are direcly involved in protein-protein interactions as well as in protein-membrane interactions
-
-
?
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
protein farnesylation is essential for early embryonic proliferation but dispensable for postnatal development and adult homeostasis. Ablation of FTase during tumor progression results in significant tumor reduction
-
-
?
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
potential role for plant enzyme in cell cycle regulation
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
potential role for plant enzyme in cell cycle regulation
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
potential role for cell cycle
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
-
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process required for the transforming activity of oncogenic variants of Ras, making enzyme a prime target for anticancer therapeutics
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process necessary for the subcellular localisation of substrate to the plasma membrane
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
enzyme responsible for catalysing isoprene lipid modifications
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
A series of steps modifies the C-terminus of Ras. Enzyme catalyses the first of these steps by transferring the farnesyl group from farnesyl diphosphates to the cysteine side chain in the CAAX sequence motif at the C-terminus of Ras
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
catalyzes the post-translational modification of many important cellular proteins
-
-
?
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
-
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process required for the transforming activity of oncogenic variants of Ras, making enzyme a prime target for anticancer therapeutics
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
process necessary for the subcellular localisation of substrate to the plasma membrane
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
a possible role for the enzyme during fruit development
-
-
-
farnesyl diphosphate + protein-cysteine
S-farnesyl protein + diphosphate
-
enzyme responsible for catalysing isoprene lipid modifications
-
-
-
additional information
?
-
Q04631
ligand interaction analysis with FTase alpha subunit, mass spectrometry, overview. The enzyme alpha-subunit interacts with Vps4A protein in vitro and in vivo
-
-
-
additional information
?
-
P29703
ligand interaction analysis with FTase alpha subunit, mass spectrometry, overview. The enzyme alpha-subunit interacts with Vps4A protein in vitro and in vivo
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Cd2+
-
substitution of the active site zinc with cadmium increases the affinity of the peptide substrate and decreases the rate constant for the chemical step
Co2+
Mg2+
Mn2+
-
in wild type FTase, Mg2+ can be replaced by Mn2+ with a 2-fold lower KMn2+ 2 mM
Zn2+
additional information
Co2+
-
evidence for a catalytically relevant interaction between the metal ion and the protein substrate in the enzyme
Mg2+
-
required, stabilizes the developing negative charge on the diphosphate as the bond breaks between the a-phosphate and the C1 atom of the farnesyl group
Mg2+
-
appears to coordinate the diphosphate moiety of farnesyl diphosphate; required
Mg2+
-
appears to coordinate the diphosphate moiety of farnesyl diphosphate; magnesium is not required for formation of the thioether product but the presence increases the single-turnover rate constant by several orders of magnitude at saturating enzyme and substrate concentrations
Mg2+
-
appears to coordinate the diphosphate moiety of farnesyl diphosphate; the magnesium affinity of enzyme increases with pH with a pka of 7.4, presumably reflecting the deprotonation of the farnesyl diphosphate to enhance magnesium coordination
Mg2+
-
enhances activity several hundred-fold, with a Km(Mg2+) value of 4 mM. Mg2+ coordinates the side chain carboxylate of Asp-beta352 and that the role of magnesium in the reaction includes positioning the FPP prior to catalysis. Mg2+ may accelerate catalysis both by stabilizing developing negative charge in the transition state and by stabilizing the active site conformation prior to catalysis
Mg2+
-
the addition of Mg2+ ions causes a conformational change in the enzyme's active site, breaking interactions known to keep farnesyl diphosphate in its inactive conformation. Wild-type protein shows relevant Mg2+ ion binding motifs. In the first binding motif, WT1, the Mg2+ ion is coordinated to D352 of beta-subunit, zinc-bound D297 of beta-subunit, two water molecules, and one oxygen atom from the alpha- and beta-phosphates of farnesyl diphosphate. The second binding motif, WT2, is identical with the exception of the zinc-bound D297 of beta-subunit being replaced by a water molecule in the Mg2+ coordination complex. In both motifs, a key hydrogen bond between a magnesium bound water and Cys1p bridges the two metallic binding sites, and thereby reduces the equilibrium distance between the reacting atoms of farnesyl diphosphate and protein-cysteine Cys1p. The free energy profiles calculated for these systems demonstrate that the two reactive atoms approach each other more readily in the presence of Mg2+. The flexible WT2 model has the lowest barrier towards the conformational change, suggesting it is the prefered Mg2+ binding motif
Zn2+
-
a single zinc ion bound to the beta subunit, near the subunit interface, which marks the location of the active site
Zn2+
-
contains one Zn2+ ion per dimer, required for catalysis and peptide binding
Zn2+
Q8WR00, Q8WR01
zinc ion is coordinated by three residues in the beta subunit: Asp-297, Cys-299, and H-362 and a water molecule; zinc ion is coordinated by three residues in the beta subunit: Asp-297, Cys-299, and H-362 and a water molecule
Zn2+
-
the zinc ion activates the cysteine thiolate for nucleophilic attack on the C1 atom of the farnesyl diphosphate substrate
Zn2+
-
required; zinc ion is coordinated by three residues in the beta subunit: Asp-297, Cys-299, and H-362 and a water molecule
Zn2+
-
zinc ion is coordinated by three residues in the beta subunit: Asp-297, Cys-299, and H-362 and a water molecule; zinc metalloenzyme; zinc plays a major catalytic role in the mechanism of enzyme, zinc seems to activate the cysteine thiol of protein substrate for attack at C-1 of the isoprenoid substrate
Zn2+
-
zinc ion is coordinated by three residues in the beta subunit: Asp-297, Cys-299, and H-362 and a water molecule
Zn2+
-
there is no significant change in Zn-ligand distances when a substrate binds, demonstrating that the Zn remains four-coordinate. Structural characterization of the zinc site
Zn2+
-
FTase is a zinc metalloenzyme with a Zn2+ ion ligated to a histidine, cysteine and aspartate
Zn2+
required, binding and coordination structure, coordinated by residues Aspbeta297, Cysbeta299 and Hisbeta362 in FTase , overview; required, binding and coordination structure, overview
Zn2+
-
zinc ion is coordinated by three residues in the beta subunit: Asp-297, Cys-299, and H-362 and a water molecule
Zn2+
zinc ion is coordinated by three residues in the beta subunit: Asp-297, Cys-299, and H-362 and a water molecule; zinc ion is coordinated by three residues in the beta subunit: Asp-297, Cys-299, and H-362 and a water molecule; zinc ion is coordinated by three residues in the beta subunit: Asp-297, Cys-299, and H-362 and a water molecule
additional information
-
a metal-assisted nucleophile is involved in the catalytic mechanism of enzyme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(1aR,2S,3aS,6aR,7aR)-2,6-dimethyl-1a-[(1E)-3-oxobut-1-en-1-yl]octahydro-5H-oxireno[4,5]cyclohepta[1,2-b]furan-5-one
-
-
(1aR,2S,3aS,6aR,7aR)-2-methyl-6-methylidene-1a-[(1E)-3-oxobut-1-en-1-yl]octahydro-5H-oxireno[4,5]cyclohepta[1,2-b]furan-5-one
-
-
(1aS,2S,3aS,6aR,7aS)-2,6-dimethyl-1a-[(1E)-3-oxobut-1-en-1-yl]octahydro-5H-oxireno[4,5]cyclohepta[1,2-b]furan-5-one
-
-
(1aS,2S,3aS,6aR,7aS)-2-methyl-6-methylidene-1a-[(1E)-3-oxobut-1-en-1-yl]octahydro-5H-oxireno[4,5]cyclohepta[1,2-b]furan-5-one
-
-
(1R,4aR,5R,7S)-5-[[(1R,4aR,8aS)-8a-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-6-methoxy-5,8-dioxo-1,4,4a,5,8,8a-hexahydronaphthalen-1-yl]methyl]-7-hydroxy-1,4a-dimethyl-6-methylidenedecahydronaphthalene-1-carbaldehyde
-
-
(1R,4aR,5R,7S)-5-[[(1R,4aR,8aS)-8a-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-6-methoxy-5,8-dioxo-1,4,4a,5,8,8a-hexahydronaphthalen-1-yl]methyl]-7-hydroxy-1,4a-dimethyl-6-methylidenedecahydronaphthalene-1-carboxylic acid
-
-
(2-[[3-(4-chlorophenyl)-4-cyano-5-(propan-2-ylsulfanyl)thiophen-2-yl]carbonyl]-1-[2-(methylsulfanyl)ethyl]hydrazinyl)acetic acid
(2E)-3-[(3aR,7S,8aS)-3,7-dimethyl-2-oxo-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-6-yl]-1-methylprop-2-en-1-yl acetate
-
-
(2Z)-3-(1H-imidazol-2-yl)-5-methylhexa-2,4-dienoic acid
-
8% inhibition at 0.001 M
(2Z)-5-methyl-3-(1-methyl-1H-imidazol-2-yl)hexa-2,4-dienoic acid
-
8% inhibition at 0.001 M
(2Z,4E,8E)-5,9,13-trimethyl-3-(1-methyl-1H-imidazol-2-yl)tetradeca-2,4,8,12-tetraenoic acid
(2Z,6E)-3-(3-methylbut-2-enyl)-7,11-dimethyldodeca-2,6,10-triene monophosphate
-
IC50: 16 nM
(2Z,6E)-3-allyl-7,11-dimethyldodeca-2,6,10-trien-1-yl 5-nitrofurfuryl N-methyl-N-(4-chlorobutyl)phosphoramidate
-
-
(2Z,6E)-3-tert-butyl-7,11-dimethyldodeca-2,6,10-trien-1-yl 5-nitrofurfuryl N-methyl-N-(4-chlorobutyl)phosphoramidate
-
-
(2Z,6E)-3-tert-butyl-7,11-dimethyldodeca-2,6,10-triene monophosphate
-
IC50: 13 nM
(2Z,6E,10E)-3-(3-methyl-1-but-2-enyl)-7,11-dimethyldodeca-2,6,10-trien-1-yl 5-nitrofurfuryl N-methyl-N-(4-chlorobutyl)phosphoramidate
-
-
(3aR,7S,8aS)-3,7-dimethyl-6-[(1E)-3-oxobut-1-en-1-yl]-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one
-
-
(3aR,7S,8aS)-6-[(1E)-3-hydroxybut-1-en-1-yl]-3,7-dimethyl-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one
-
-
(3aR,7S,8aS)-7-methyl-3-methylidene-6-[(1E)-3-oxobut-1-en-1-yl]-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one
-
-
(3aR,8S,9aS)-6-acetyl-3,8-dimethyl-3,3a,4,8,9,9a-hexahydro-2H-cyclohepta[1,2-b:4,5-b']difuran-2-one
-
-
(3R,3aR,7S,8aS)-3,7-dimethyl-6-(3-oxobutyl)-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one
-
-
(3R,3aR,7S,8aS)-6-(3-hydroxybutyl)-3,7-dimethyl-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one
-
-
(4aS,5R,8aR)-4a-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-methoxy-5-[[(1S,3S,7S,8aS)-1,3,7-trihydroxy-5,5,8a-trimethyl-2-methylidenedecahydronaphthalen-1-yl]methyl]-4a,5,8,8a-tetrahydronaphthalene-1,4-dione
-
-
(4aS,5R,8aR)-4a-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-methoxy-6-methyl-5-[[(1R,8aS)-5,5,8a-trimethyl-2-methylidene-3-oxodecahydronaphthalen-1-yl]methyl]-4a,5,8,8a-tetrahydronaphthalene-1,4-dione
-
-
(4aS,5R,8aR)-4a-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-5-[[(1R,3S,5R,8aS)-3-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidenedecahydronaphthalen-1-yl]methyl]-2-methoxy-4a,5,8,8a-tetrahydronaphthalene-1,4-dione
-
-
(4aS,5R,8aR)-4a-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-5-[[(1R,3S,7S,8aS)-3,7-dihydroxy-5,5,8a-trimethyl-2-methylidenedecahydronaphthalen-1-yl]methyl]-2-methoxy-4a,5,8,8a-tetrahydronaphthalene-1,4-dione
-
-
(4aS,5R,8aR)-4a-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-5-[[(1R,3S,8aS)-3-hydroxy-5,5,8a-trimethyl-2-methylidenedecahydronaphthalen-1-yl]methyl]-2-methoxy-4a,5,8,8a-tetrahydronaphthalene-1,4-dione
-
-
(4aS,5R,8aR)-4a-(5-hydroxy-7-methoxy-4-oxo-4H-chromen-2-yl)-2-methoxy-6-methyl-5-[[(1R,8aS)-5,5,8a-trimethyl-2-methylidene-3-oxodecahydronaphthalen-1-yl]methyl]-4a,5,8,8a-tetrahydronaphthalene-1,4-dione
-
-
(4aS,5S,8aR)-4a-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-5-[[(1R,2R,7S,8aS)-2,7-dihydroxy-2,5,5,8a-tetramethyldecahydronaphthalen-1-yl]methyl]-6-hydroxy-2-methoxy-4a,5,8,8a-tetrahydronaphthalene-1,4-dione
-
-
(4E,8E)-2-(ethoxycarbonyl)-5,9,13-trimethyl-2-[3-(1-methyl-1H-imidazol-2-yl)propyl]tetradeca-4,8,12-trienoic acid
(4S)-4-([[5-(butan-2-yl)-3-(4-chlorophenyl)-4-cyanothiophen-2-yl]carbonyl]amino)-5-tert-butoxy-5-oxopentanoic acid
(E,E)-8-O-(3-benzoylbenzyl)-3,7-dimethyl-2,6-octadiene 1-diphosphate
-
-
(E,E)-8-O-(4-benzoylbenzyl)-3,7-dimethyl-2,6-octadiene 1-diphosphate
-
-
(S)-N-(4-(3,4-dichlorophenoxy)benzyl)-6-(1H-indol-3-yl)piperazine-2,5-dione
-
dual inhibitor for both farnesyl transferase and geranygeranyltransferase-I. Compound occupies both isoprenoid and peptide substrate binding sites
(S)-N-(4-(3-chlorophenoxy)benzyl)-6-(1H-indol-3-yl)piperazine-2,5-dione
-
dual inhibitor for both farnesyl transferase and geranygeranyltransferase-I
1,4,8,10-tetrahydroxy-6-[(1E)-3-[(3S,8aS)-3-hydroxy-5,5,8a-trimethyl-2-methylidenedecahydronaphthalen-1-yl]-1-methylprop-1-en-1-yl]-5,6-dihydro-7H-benzo[c]xanthen-7-one
-
-
1,5-dimethyl-1H-imidazole-4-sulfonic acid (5-bromo-2-fluorobenzyl)-[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-amide
-
98% inhibition at 50 nM
1,5-dimethyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(4-ethanesulfonyl-benzyl)-amide
-
97% inhibition at 50 nM
1,5-dimethyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(4-methanesulfonyl-benzyl)-amide
-
92% inhibition at 50 nM
1-(1-[3,4-bis[(hydroxyacetyl)amino]phenyl]-4,4-dicyano-1-oxobut-3-en-2-yl)-3-(dimethylamino)pyridinium
-
-
1-(1H-imidazol-5-ylmethyl)-7-pyridin-4-yl-4-[[2-(trifluoromethoxy)phenyl]carbonyl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine
-
-
1-(2-chlorophenyl)-N-[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinolin-3-yl]-N-[4-(methylsulfonyl)benzyl]methanesulfonamide
-
99% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid (2-bromo-allyl)-[1-(3-methyl-3H-imidazol-4-ylmethyl)-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl]-amide
-
97% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid (2-bromo-allyl)-[6-cyano-1-(3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-amide
-
94% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid (4-benzenesulfonylbenzyl)-[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-amide
-
99% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid (4-methanesulfonylbenzyl)-[1-(3-methyl-3H-imidazol-4-ylmethyl)-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl]-amide
-
98% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid benzyl-[6-cyano-1-(3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-amide
-
93% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid ethyl-[1-(3-methyl-3H-imidazol-4-ylmethyl)-6-phenyl-1,2,3,4-tetrahydro-quinolin-3-yl]amide
-
86% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid [1-(3-methyl-3H-imidazol-4-ylmethyl)-6-phenyl-1,2,3,4-tetrahydro-quinolin-3-yl]-(2-pyrrol-1-yl-ethyl)-amide
-
90% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-yl-methyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(3-methoxy-propyl)-amide
-
-
1-methyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(4,4-dioxo-3,4-dihydro-2H-4lambda6-benzo[1,4]oxathin-7-ylmethyl)-amide
-
99% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(4-ethanesulfonyl-benzyl)-amide
-
complete inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(4-fluoro-benzyl)-amide
-
99% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(4-methanesulfonyl-benzyl)-amide
-
complete inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(5-trifluoromethyl-furan-2-ylmethyl)-amide
-
97% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-[2-(2-fluoro-phenyl)-ethyl]-amide
-
complete inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-[2-(2-oxo-pyrrolidin-1-yl)-ethyl]-amide
-
99% inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-[2-(4-fluoro-phenyl)-ethyl]-amide
-
complete inhibition at 50 nM
1-methyl-1H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-butyl]-amide
-
99% inhibition at 50 nM
1-methyl-1H-pyrazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(2-fluoro-benzyl)-amide
-
94% inhibition at 50 nM
1-methyl-N-(2-methylbenzyl)-N-[1-[(1-methyl-1H-imidazol-5-yl)methyl]-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl]-1H-imidazole-4-sulfonamide
-
46% inhibition at 50 nM
1-methyl-N-[1-[(1-methyl-1H-imidazol-5-yl)methyl]-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl]-1H-imidazole-4-sulfonamide
-
80% inhibition at 50 nM
1-methyl-N-[1-[(1-methyl-1H-imidazol-5-yl)methyl]-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl]-N-(2-methylprop-2-en-1-yl)-1H-imidazole-4-sulfonamide
-
99% inhibition at 50 nM
1-methyl-N-[1-[(1-methyl-1H-imidazol-5-yl)methyl]-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl]-N-prop-2-en-1-yl-1H-imidazole-4-sulfonamide
-
98% inhibition at 50 nM
1-methyl-N-[1-[(1-methyl-1H-imidazol-5-yl)methyl]-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl]-N-prop-2-yn-1-yl-1H-imidazole-4-sulfonamide
-
95% inhibition at 50 nM
1-methyl-N-[1-[(1-methyl-1H-imidazol-5-yl)methyl]-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl]-N-[(5-methylisoxazol-4-yl)methyl]-1H-imidazole-4-sulfonamide
1-methyl-N-[1-[(1-methyl-1H-imidazol-5-yl)methyl]-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl]-N-[2-(methylsulfonyl)ethyl]-1H-imidazole-4-sulfonamide
-
99% inhibition at 50 nM
1-methyl-N-[1-[(1-methyl-1H-imidazol-5-yl)methyl]-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl]-N-[[5-(trifluoromethyl)furan-2-yl]methyl]-1H-imidazole-4-sulfonamide
-
88% inhibition at 50 nM
1-methylethyl 4-[([1-[(1-methyl-1H-imidazol-5-yl)methyl]-6-phenyl-1,2,3,4-tetrahydroquinolin-3-yl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino)methyl]piperidine-1-carboxylate
1-methylethyl 4-[[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4,6,7-hexahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]methyl]piperidine-1-carboxylate
-
97% inhibition at 50 nM
1-[(3aR,7S,8aS)-3,7-dimethyl-2-oxo-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-6-yl]-3-(1-hydroxyethoxy)butyl acetate
-
-
1-[(3aR,7S,8aS)-3,7-dimethyl-2-oxo-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-6-yl]butane-1,3-diyl diacetate
-
-
1-[(3aR,7S,8aS)-7-methyl-3-methylidene-2-oxo-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-6-yl]-3-oxobutyl acetate
-
-
1-[(3aR,7S,8aS)-7-methyl-3-methylidene-2-oxo-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-6-yl]butane-1,3-diyl diacetate
-
-
1-[(3Z)-1-(4-bromophenyl)-4-cyano-5,5-dihydroxy-1-oxohept-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[(3Z)-1-(4-chlorophenyl)-4-cyano-5,5-dihydroxy-1-oxohept-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[(3Z)-1-[3,4-bis[(hydroxyacetyl)amino]phenyl]-4-cyano-5,5-dihydroxy-1-oxohept-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[(3Z)-4-cyano-1-(3,4-dimethoxyphenyl)-5,5-dihydroxy-1-oxohept-3-en-2-yl]-3-methoxypyridinium
-
-
1-[(3Z)-4-cyano-1-(4-cyanophenyl)-5,5-dihydroxy-1-oxohept-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[(3Z)-4-cyano-1-(4-fluorophenyl)-5,5-dihydroxy-1-oxohept-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[(3Z)-4-cyano-5,5-dihydroxy-1-(4-methoxyphenyl)-1-oxohept-3-en-2-yl]-2,4-dimethylpyridinium
-
-
1-[(3Z)-4-cyano-5,5-dihydroxy-1-(4-methoxyphenyl)-1-oxohept-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[(3Z)-4-cyano-5,5-dihydroxy-1-(4-methoxyphenyl)-1-oxohept-3-en-2-yl]-3-methoxypyridinium
-
-
1-[(3Z)-4-cyano-5,5-dihydroxy-1-(4-methylphenyl)-1-oxohept-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[(3Z)-4-cyano-5,5-dihydroxy-1-(4-nitrophenyl)-1-oxohept-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[(3Z)-4-cyano-5,5-dihydroxy-1-oxo-1-(3,4,5-trimethoxyphenyl)hept-3-en-2-yl]-2,4-dimethylpyridinium
-
-
1-[(3Z)-4-cyano-5,5-dihydroxy-1-oxo-1-(3,4,5-trimethoxyphenyl)hept-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[(3Z)-4-cyano-5,5-dihydroxy-1-oxo-1-phenylhept-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[(3Z)-4-cyano-5,5-dihydroxy-1-oxo-1-phenylhept-3-en-2-yl]-3-methylpyridinium
-
-
1-[1-(4-bromophenyl)-4,4-dicyano-1-oxobut-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[1-(4-chlorophenyl)-4,4-dicyano-1-oxobut-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[4,4-dicyano-1-(3,4-dimethoxyphenyl)-1-oxobut-3-en-2-yl]-3-methoxypyridinium
-
-
1-[4,4-dicyano-1-(4-cyanophenyl)-1-oxobut-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[4,4-dicyano-1-(4-fluorophenyl)-1-oxobut-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[4,4-dicyano-1-(4-methoxyphenyl)-1-oxobut-3-en-2-yl]-2,4-dimethylpyridinium
-
-
1-[4,4-dicyano-1-(4-methoxyphenyl)-1-oxobut-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[4,4-dicyano-1-(4-methylphenyl)-1-oxobut-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[4,4-dicyano-1-(4-nitrophenyl)-1-oxobut-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
1-[4,4-dicyano-1-oxo-1-(3,4,5-trimethoxyphenyl)but-3-en-2-yl]-2,4-dimethylpyridinium
-
-
1-[4,4-dicyano-1-oxo-1-(3,4,5-trimethoxyphenyl)but-3-en-2-yl]-3-(dimethylamino)pyridinium
-
-
18-oxa-2,5,9,11-tetraazahexacyclo[17.6.2.22,5.113,17.07,11.022,26]triaconta-1(26),7,9,13(28),14,16,19,21,22,24,26-undecaene-16-carbonitrile
-
-
2,2,2-trifluoroethyl 4-[[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4,6,7-hexahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]methyl]piperidine-1-carboxylate
-
91% inhibition at 50 nM
2-amino-3-[2-butyl-4-(naphthalen-1-ylcarbonyl)piperazin-1-yl]propane-1-thiol
-
-
2-methylpropyl 4-[([6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinolin-3-yl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino)methyl]piperidine-1-carboxylate
-
98% inhibition at 50 nM
2-methylpropyl 4-[[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]methyl]piperidine-1-carboxylate
2-[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinolin-3-yl](2-fluorobenzyl)amino]-2-oxoethyl acetate
-
33% inhibition at 50 nM
29-oxo-18-oxa-2,6,9,11-tetraazahexacyclo[17.5.3.12,5.113,17.07,11.022,26]nonacosa-7,9,13(28),14,16,19,21,26-octaene-16-carbonitrile
-
-
3,4-dihydro-2H-benzo[b][1,4]dioxepine-7-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydroquinolin-3-yl]-(4-methanesulfonyl-benzyl)-amide
-
97% inhibition at 50 nM
3-(1H-imidazol-2-yl)-5-methylhex-4-enoic acid
-
21% inhibition at 0.001 M
3-(3-methyl-2-butenyl)-7,11-dimethyldodeca-2(Z),6(E),10-triene 1-diphosphate
-
farnesylation of dansyl-GCKVL, IC5=: 510 nM
3-(4-chlorophenyl)-4-cyano-1-methyl-5-[(1-methylethyl)sulfanyl]-1H-pyrrole-2-carboxylic acid
-
-
3-(4-chlorophenyl)-4-cyano-5-(cyclohexylsulfanyl)thiophene-2-carboxylic acid
-
-
3-(4-chlorophenyl)-4-cyano-5-(ethylsulfanyl)thiophene-2-carboxylic acid
-
-
3-(4-chlorophenyl)-4-cyano-5-(methylsulfanyl)thiophene-2-carboxylic acid
-
-
3-(4-chlorophenyl)-4-cyano-5-(morpholin-4-ylsulfanyl)thiophene-2-carboxylic acid
-
-
3-(4-chlorophenyl)-4-cyano-5-[(1-methylethyl)sulfanyl]furan-2-carboxylic acid
-
-
3-(4-chlorophenyl)-4-cyano-5-[(1-methylethyl)sulfanyl]thiophene-2-carboxamide
-
-
3-(4-chlorophenyl)-4-cyano-5-[(1-methylethyl)sulfanyl]thiophene-2-carboxylic acid
-
-
3-(4-chlorophenyl)-4-cyano-5-[(1-methylpropyl)sulfanyl]thiophene-2-carboxylic acid
-
-
3-(4-chlorophenyl)-4-cyano-5-[(2-methylpropyl)sulfanyl]thiophene-2-carboxylic acid
-
-
3-(4-chlorophenyl)-4-cyano-N'-[2-(methylsulfanyl)ethyl]-5-(propan-2-ylsulfanyl)thiophene-2-carbohydrazide
3-(4-chlorophenyl)-4-cyano-N-(naphthalen-1-yl)-5-(propan-2-ylsulfanyl)thiophene-2-carboxamide
3-(4-chlorophenyl)-4-cyano-N-cyclopropyl-5-[(1-methylethyl)sulfanyl]thiophene-2-carboxamide
-
-
3-(4-chlorophenyl)-4-cyano-N-[2-(methylsulfanyl)ethyl]-5-(propan-2-ylsulfanyl)thiophene-2-carboxamide
3-(4-chlorophenyl)-5-([[1-(4-cyanobenzyl)-1H-imidazol-4-yl]methyl][[1-(4-cyanobenzyl)-1H-imidazol-5-yl]methyl]amino)-4-ethynylthiophene-2-carboxylic acid
3-hydroxy-1-[(3aR,7S,8aS)-7-methyl-3-methylidene-2-oxo-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-6-yl]butyl acetate
-
-
3-methyl-2-[2-oxo-2-(10H-phenothiazin-10-yl)ethyl]indeno[1,2-c]pyrazol-4(2H)-one
-
most potent in vitro cytostatic activity inhibiting the growth of HCT-116, LOX IMVI and SK-MEL-5 cell lines
3-methyl-3H-imidazole-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(4-methanesulfonyl-benzyl)-amide
-
complete inhibition at 50 nM
3-methyl-thiophene-4-sulfonic acid [6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(4-methanesulfonyl-benzyl)-amide
-
97% inhibition at 50 nM
3-[(tert-butylcarbamoyl-methyl)-(1-methyl-1H-imidazol-4-sulfonyl)-amino]-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-6-carboxylic acid
-
80% inhibition at 50 nM
3-[(tert-butylcarbamoyl-methyl)-(1-methyl-1H-imidazol-4-sulfonyl)-amino]-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-6-carboxylic acid benzylamide
-
59% inhibition at 50 nM
3-[(tert-butylcarbamoyl-methyl)-(1-methyl-1H-imidazol-4-sulfonyl)-amino]-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-6-carboxylic acid tert-butylamide
-
25% inhibition at 50 nM
3-[3-[2-([2-[1-(tert-butoxycarbonyl)piperidin-4-yl]-1-([(4-cyanophenyl)[(1-methyl-1H-imidazol-5-yl)methyl]amino]methyl)ethyl]sulfamoyl)benzyl]phenyl]propanoic acid
3-[[2-(tert-butylamino)-2-oxoethyl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]-1-[(1-methyl-1H-imidazol-5-yl)methyl]-N-(1-methylpropyl)-1,2,3,4-tetrahydroquinoline-6-carboxamide
-
35% inhibition at 50 nM
3-[[2-(tert-butylamino)-2-oxoethyl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]-N,N-diethyl-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinoline-6-carboxamide
-
69% inhibition at 50 nM
3-[[2-(tert-butylamino)-2-oxoethyl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]-N-(1-methylethyl)-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinoline-6-carboxamide
-
46% inhibition at 50 nM
3-[[2-(tert-butylamino)-2-oxoethyl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]-N-cyclohexyl-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinoline-6-carboxamide
-
66% inhibition at 50 nM
3-[[2-(tert-butylamino)-2-oxoethyl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]-N-methyl-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinoline-6-carboxamide
-
69% inhibition at 50 nM
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-(3-cyclohexylpropanoyl)-N-(pyridin-3-ylmethyl)piperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-(4-oxopentanoyl)-N-(pyridin-3-ylmethyl)piperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-(5-oxohexanoyl)-N-(pyridin-3-ylmethyl)piperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-(6-oxoheptanoyl)-N-(pyridin-3-ylmethyl)piperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-(cycloheptylcarbonyl)-N-(pyridin-3-ylmethyl)piperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-(cyclopentylcarbonyl)-N-(pyridin-3-ylmethyl)piperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-(ethoxyacetyl)-N-(pyridin-3-ylmethyl)piperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-hexanoyl-N-(pyridin-3-ylmethyl)piperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-pentanoyl-N-(pyridin-3-ylmethyl)piperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-pentanoyl-N-pyrazin-2-ylpiperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-pentanoyl-N-pyridin-3-ylpiperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[(3,3-dihydroxycyclobutyl)carbonyl]-N-(pyridin-3-ylmethyl)piperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-[4-(dimethylamino)-4-oxobutanoyl]-N-(pyridin-3-ylmethyl)piperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N-(1-oxidopyridin-3-yl)-1-pentanoylpiperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N-(1H-imidazol-4-ylmethyl)-1-pentanoylpiperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N-(2,5-dihydro-1H-imidazol-5-ylmethyl)-1-pentanoylpiperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N-isoxazol-5-yl-1-pentanoylpiperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N-[2-(1H-imidazol-4-yl)ethyl]-1-pentanoylpiperazine-2-carboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-(1-methylethyl)-N2-(pyridin-3-ylmethyl)piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-(2-methylpropyl)-N2-(pyridin-3-ylmethyl)piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-(cyclohexylmethyl)-N2-(pyridin-3-ylmethyl)piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-butyl-N2-(pyridin-3-ylmethyl)piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-cycloheptyl-N2-(pyridin-3-ylmethyl)piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-cyclohexyl-N2-(pyridin-3-ylmethyl)piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-cyclohexyl-N2-[(3,5-dimethylisoxazol-4-yl)methyl]piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-cyclohexyl-N2-[2-(1-methyl-1H-imidazol-5-yl)ethyl]piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-cyclohexyl-N2-[2-(1H-imidazol-4-yl)ethyl]piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-cyclohexyl-N2-[2-(6-methylpyridin-3-yl)ethyl]piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-cyclohexyl-N2-[3-(1H-imidazol-4-yl)propyl]piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-cyclohexyl-N2-[3-(2-oxopyrrolidin-1-yl)propyl]piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-cyclopentyl-N2-(pyridin-3-ylmethyl)piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-cyclopropyl-N2-(pyridin-3-ylmethyl)piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-propyl-N2-(pyridin-3-ylmethyl)piperazine-1,2-dicarboxamide
-
-
4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-N1-tert-butyl-N2-(pyridin-3-ylmethyl)piperazine-1,2-dicarboxamide
-
-
4-(3-{[(4-cyano-3-naphthalen-1-yl-phenyl)-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-methyl}-phenyl)-pyridine-2-carbonitrile
-
IC50: 0.37 nM, selective inhibitor
4-(4-chlorophenyl)-2-[(1-methylethyl)sulfanyl]-1,3-thiazole-5-carboxylic acid
-
-
4-(4-chlorophenyl)-5-(hydroxyacetyl)-2-[(1-methylethyl)sulfanyl]thiophene-3-carbonitrile
-
-
4-(4-chlorophenyl)-5-(methoxyacetyl)-2-[(1-methylethyl)sulfanyl]thiophene-3-carbonitrile
-
-
4-([(2-carboxy-furan-5-sulfonyl)-[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-amino]-methyl)-piperidine-1-carboxylic acid methyl ester
-
89% inhibition at 50 nM
4-([(benzo[1,2,5]oxadiazole-4-sulfonyl)-[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-amino]-methyl)-piperidine-1-carboxylic acid methyl ester
-
99% inhibition at 50 nM
4-([(benzo[1,2,5]thiadiazole-4-sulfonyl)-[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-amino]-methyl)-piperidine-1-carboxylic acid methyl ester
-
98% inhibition at 50 nM
4-([[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-cyclopropanesulfonyl-amino]-methyl)-piperidine-1-carboxylic acid methyl ester
-
37% inhibition at 50 nM
4-([[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-ethanesulfonyl-amino]-methyl)-piperidine-1-carboxylic acid methyl ester
-
44% inhibition at 50 nM
4-([[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-methanesulfonylmethanesulfonyl-amino]-methyl)-piperidine-1-carboxylic acid methyl ester
-
15% inhibition at 50 nM
4-ethynyl-5-([[1-(4-nitrobenzyl)-1H-imidazol-5-yl]methyl]amino)-3-phenylthiophene-2-carboxylic acid
4-[(3'-Chloro-biphenyl-3-ylmethyl)-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-2-naphthalen-1-yl-benzonitrile
-
IC50: 0.45 nM, selective inhibitor
4-[(3-cyano-benzyl)-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-2-naphthalen-1-yl-benzonitrile
-
IC50: 0.39 nM, selective inhibitor
4-[(3-Methyl-3H-imidazol-4-ylmethyl)-amino]-2-naphthalen-1-yl-benzonitrile
-
IC50: 31 nM
4-[(4-cyano-benzyl)-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-2-naphthalen-1-yl-benzonitrile
-
IC50: 1.5 nM, selective inhibitor
4-[(5-[[4-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl)azepan-1-yl]methyl]-1H-imidazol-1-yl)methyl]benzonitrile
-
-
4-[(5-[[4-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl)piperidin-1-yl]methyl]-1H-imidazol-1-yl)methyl]benzonitrile
-
-
4-[(5-[[4-(5-oxido-7-propyl-7,12-dihydrodibenzo[c,f][1,2,8]oxathiazocin-12-yl)azepan-1-yl]methyl]-1H-imidazol-1-yl)methyl]benzonitrile
-
-
4-[(5-[[4-(7-butyl-5-oxido-7,12-dihydrodibenzo[c,f][1,2,8]oxathiazocin-12-yl)azepan-1-yl]methyl]-1H-imidazol-1-yl)methyl]benzonitrile
-
-
4-[(5-[[4-(7-methyl-5-oxido-7,12-dihydrodibenzo[c,f][1,2,8]oxathiazocin-12-yl)azepan-1-yl]methyl]-1H-imidazol-1-yl)methyl]benzonitrile
-
-
4-[(5-[[4-(7-methyl-5-oxido-7,12-dihydrodibenzo[c,f][1,2,8]oxathiazocin-12-yl)piperidin-1-yl]methyl]-1H-imidazol-1-yl)methyl]benzonitrile
-
-
4-[([6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinolin-3-yl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino)methyl]benzoic acid
-
66% inhibition at 50 nM
4-[2-[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]-2-(1H-imidazol-5-yl)ethyl]benzonitrile
binds into the CAAX peptide site and competes with the CAAX substrate of FTase; binds into the CAAX peptide site and competes with the CAAX substrate of FTase
4-[Biphenyl-3-ylmethyl-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-2-naphthalen-1-yl-benzonitrile
-
IC50: 1.5 nM
4-[Hexyl-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-2-naphthalen-1-yl-benzonitrile
-
IC50: 1.9 nM
4-[Methyl-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-2-naphthalen-1-yl-benzonitrile
-
IC50: 38 nM
4-[N, N -bis((1H-imidazol-4-yl)methyl)aminomethyl]-2-(1-(o-tolyl))benzoylmethionine trifluoroacetate
-
IC50: 1.7 nM
4-[N-(1-H-imidazol-4-yl)methylamino]-2-(2-methoxyphenyl)-benzoylmethionine
-
IC50: 9.5 nM
4-[N-(1-H-imidazol-4-yl)methylamino]-2-(2-methylphenyl)-benzoylmethionine
-
IC50: 2.8 nM
4-[[(6-cyano-1-pyridin-3-ylmethyl-1,2,3,4-tetrahydro-quinolin-3-yl)-(pyridine-2-sulfonyl)-amino]-methyl]-piperidine-1-carboxylic acid methyl ester
-
35% inhibition at 50 nM
4-[[4-([[4-(4-chlorophenyl)-3-ethynylthiophen-2-yl]amino]methyl)-1H-imidazol-1-yl]methyl]benzonitrile
4-[[5-([4-[7-(3-morpholin-4-ylpropyl)-5-oxido-7,12-dihydrodibenzo[c,f][1,2,8]oxathiazocin-12-yl]azepan-1-yl]methyl)-1H-imidazol-1-yl]methyl]benzonitrile
-
-
4-[[[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(1,5-dimethyl-1H-imidazole-4-sulfonyl)-amino]-methyl]-piperidine-1-carboxylic acid methyl ester
-
complete inhibition at 50 nM
4-[[[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(1,5-dimethyl-1H-imidazole-4-sulfonyl)-amino]-methyl]-piperidine-1-carboxylic acid tert-butyl ester
-
98% inhibition at 50 nM
4-[[[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(2-oxo-2H-chromene-6-sulfonyl)-amino]-methyl]-piperidine-1-carboxylic acid methyl ester
-
68% inhibition at 50 nM
4-[[[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(3,4-dihydro-2H-benzo[b][1,4]dioxepine-7-sulfonyl)-amino]-methyl]-piperidine-1-carboxylic acid methyl ester
-
99% inhibition at 50 nM
4-[[[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(3-methyl-3H-imidazole-4-sulfonyl)-amino]-methyl]-piperidine-1-carboxylic acid methyl ester
-
99% inhibition at 50 nM
4-[[[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(pyridine-2-sulfonyl)-amino]-methyl]-piperidine-1-carboxylic acid ethylamide
-
98% inhibition at 50 nM
4-[[[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(pyridine-2-sulfonyl)-amino]-methyl]-piperidine-1-carboxylic acid isobutyl ester
4-[[[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(pyridine-2-sulfonyl)-amino]-methyl]-piperidine-1-carboxylic acid methyl ester
4-[[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4,6,7-hexahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]methyl]-N,N-dimethylpiperidine-1-carboxamide
-
complete inhibition at 50 nM
4-[[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4,6,7-hexahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]methyl]-N-(1-methylethyl)piperidine-1-carboxamide
-
complete inhibition at 50 nM
4-[[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]methyl]-N-ethylpiperidine-1-carboxamide
5,7-dihydroxy-2-[(5R)-1-hydroxy-5-[[(3S,8aS)-3-hydroxy-5,5,8a-trimethyl-2-methylidenedecahydronaphthalen-1-yl]methyl]-2-methoxy-6-methyl-4-oxo-1,5,8,8a-tetrahydronaphthalen-4a(4H)-yl]-4H-chromen-4-one
-
-
5,7-dihydroxy-2-[(5R)-1-hydroxy-5-[[(3S,8aS)-3-hydroxy-5,5,8a-trimethyl-2-methylidenedecahydronaphthalen-1-yl]methyl]-6-methyl-2-oxo-1,5,8,8a-tetrahydronaphthalen-4a(2H)-yl]-4H-chromen-4-one
-
-
5,9,13-trimethyl-8,12-tetradecadiene-2,3-dione
-
0.093 mM causes a 94% reduction in enzyme activity after 30 min
5,9-dimethyl-8-decene-2,3-dione
-
0.017 mM causes a 62% reduction in enzyme activity after 30 min
5-(butylsulfanyl)-3-(4-chlorophenyl)-4-cyanothiophene-2-carboxylic acid
-
-
5-([[1-(4-cyanobenzyl)-1H-imidazol-5-yl]methyl]amino)-4-ethynyl-3-phenylthiophene-2-carboxylic acid
5-acetyl-4-(4-chlorophenyl)-2-[(1-methylethyl)sulfanyl]thiophene-3-carbonitrile
-
-
5-methyl-3-(1-methyl-1H-imidazol-2-yl)hex-4-enoic acid
-
25% inhibition at 0.001 M
5-[(3-cyano-benzyl)-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-2'-methyl-biphenyl-2-carbonitrile
-
IC50: 0.97 nM, selective inhibitor
5-[(4-cyano-benzyl)-(3-methyl-3H-imidazol-4-ylmethyl)-amino]-2'-methyl-biphenyl-2-carbonitrile
-
IC50: 10 nM, selective inhibitor
5-[(tert-butoxycarbonyl)[[1-(4-cyanobenzyl)-1H-imidazol-5-yl]methyl]amino]-3-(4-chlorophenyl)-4-ethynylthiophene-2-carboxylic acid
5-[(tert-butoxycarbonyl)[[1-(4-nitrobenzyl)-1H-imidazol-4-yl]methyl]amino]-3-(4-chlorophenyl)-4-ethynylthiophene-2-carboxylic acid
5-[(tert-butoxycarbonyl)[[1-(4-nitrobenzyl)-1H-imidazol-5-yl]methyl]amino]-3-(4-chlorophenyl)-4-ethynylthiophene-2-carboxylic acid
5-[4-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-2-[(pyridin-3-ylmethyl)carbamoyl]piperazin-1-yl]-5-oxopentyl acetate
-
-
6-([6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinolin-3-yl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino)hexanamide
-
98% inhibition at 50 nM
6-[(4-hydroxyphenyl)(1H-imidazol-1-yl)methyl]-4-phenyl-1,2-dihydroquinolin-2-ol
-
-
6-[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]hexanamide
-
81% inhibition at 50 nM
6-[[[6-cyano-1-(3-methyl-3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(pyridine-2-sulfonyl)-amino]-methyl]-pyridine-2-carboxylic acid methyl ester
-
96% inhibition at 50 nM
6-[[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]methyl]pyridine-2-carboxylic acid
-
97% inhibition at 50 nM
benzyl 4-[[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4,6,7-hexahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]methyl]piperidine-1-carboxylate
-
98% inhibition at 50 nM
Biphenyl-3-carboxylic acid (4-cyano-3-naphthalen-1-yl-phenyl)-(3-methyl-3H-imidazol-4-ylmethyl)-amide
-
IC50: 14 nM
Biphenyl-3-sulfonic acid (4-cyano-3-naphthalen-1-yl-phenyl)-(3-methyl-3H-imidazol-4-ylmethyl)-amide
-
IC50: 18 nM
di-tert-butyl 2-[(2E,6E,10E)-1,3,7-trimethyl-1-(1-methyl-1H-imidazol-2-yl)dodeca-2,6,10-trien-1-yl]butanedioate
ED5
-
i.e. N-(N-tert-butoxycarbonylpiperidin-4-ylmethyl), N-(2-[((4-cyanophenyl)-3-methyl-3H-imidazol-4-ylmethyl)-amino]-ethyl) 2-methylbenzenesulfonamide, an ethylenediamine-scaffold inhibitor
ethyl (2-[[3-(4-chlorophenyl)-4-cyano-5-(propan-2-ylsulfanyl)thiophen-2-yl]carbonyl]-1-[2-(methylsulfanyl)ethyl]hydrazinyl)acetate
ethyl 3-(4-chlorophenyl)-4-cyano-5-[(1-methylethyl)sulfanyl]thiophene-2-carboxylate
-
-
ethyl 3-(4-chlorophenyl)-4-ethynyl-5-[(1H-imidazol-4-ylacetyl)amino]thiophene-2-carboxylate
ethyl 3-(4-chlorophenyl)-5-([[1-(4-cyanobenzyl)-1H-imidazol-4-yl]methyl]amino)-4-ethynylthiophene-2-carboxylate
-
-
ethyl 3-(4-chlorophenyl)-5-([[1-(4-cyanobenzyl)-1H-imidazol-4-yl]methyl][[1-(4-cyanobenzyl)-1H-imidazol-5-yl]methyl]amino)-4-ethynylthiophene-2-carboxylate
ethyl 4-ethynyl-5-([[1-(4-nitrobenzyl)-1H-imidazol-5-yl]methyl]amino)-3-phenylthiophene-2-carboxylate
ethyl 4-[([6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinolin-3-yl][(1-methyl-1H-imidazol-4-yl)sulfonyl]amino)methyl]piperidine-1-carboxylate
-
98% inhibition at 50 nM
ethyl 4-[[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4,6,7-hexahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]methyl]piperidine-1-carboxylate
ethyl 4-[[[6-cyano-1-[(1-methyl-1H-imidazol-5-yl)methyl]-1,2,3,4-tetrahydroquinolin-3-yl](pyridin-2-ylsulfonyl)amino]methyl]piperidine-1-carboxylate
ethyl 5-([[1-(4-cyanobenzyl)-1H-imidazol-5-yl]methyl]amino)-4-ethynyl-3-phenylthiophene-2-carboxylate
ethyl 5-[(tert-butoxycarbonyl)[[1-(4-cyanobenzyl)-1H-imidazol-5-yl]methyl]amino]-3-(4-chlorophenyl)-4-ethynylthiophene-2-carboxylate
-
-
ethyl 5-[(tert-butoxycarbonyl)[[1-(4-nitrobenzyl)-1H-imidazol-4-yl]methyl]amino]-3-(4-chlorophenyl)-4-ethynylthiophene-2-carboxylate
-
-
ethyl 5-[(tert-butoxycarbonyl)[[1-(4-nitrobenzyl)-1H-imidazol-5-yl]methyl]amino]-3-(4-chlorophenyl)-4-ethynylthiophene-2-carboxylate
ethyl [[2-([[3-(4-chlorophenyl)-4-cyano-5-(propan-2-ylsulfanyl)thiophen-2-yl]carbonyl]amino)ethyl]sulfanyl]acetate
farnesyltransferase inhibitors I and II
-
peptidomimemtic inhibitors, inhibitor I: 50% inhibition at 270 nM, inhibitor II: 50% inhibition at 0.97 nM
-